[go: up one dir, main page]

US20060078552A1 - Hybrid and single chain meganucleases and use thereof - Google Patents

Hybrid and single chain meganucleases and use thereof Download PDF

Info

Publication number
US20060078552A1
US20060078552A1 US10/507,736 US50773605A US2006078552A1 US 20060078552 A1 US20060078552 A1 US 20060078552A1 US 50773605 A US50773605 A US 50773605A US 2006078552 A1 US2006078552 A1 US 2006078552A1
Authority
US
United States
Prior art keywords
meganuclease
domain
dodecapeptide
hybrid
derived
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/507,736
Other languages
English (en)
Inventor
Sylvain Arnould
Patrick Chames
Andre Choulika
Jean-Charles Epinat
Emmanuel Lacroix
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cellectis SA
Original Assignee
Cellectis SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=28041871&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20060078552(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cellectis SA filed Critical Cellectis SA
Priority to US10/507,736 priority Critical patent/US20060078552A1/en
Assigned to CELLECTIS reassignment CELLECTIS ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CHOULIKA, ANDRE', ARNOULD, SYLVAIN, CHAMES, PATRICK, EPINAT, JEAN-CHARLES, LACROIX, EMMANUEL
Publication of US20060078552A1 publication Critical patent/US20060078552A1/en
Priority to US12/482,124 priority patent/US20100151556A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Definitions

  • This patent application relates to hybrid and/or single-chain rare-cutting endonucleases, called meganucleases, which recognize and cleave a specific nucleotide sequence, to polynucleotide sequences encoding for said rare-cutting endonucleases, to a vector comprising one of said polynucleotide sequences, to a cell or animal comprising one of said polynucleotide sequences or said rare-cutting endonucleases, to a process for producing one of said rare-cuuting endonucleases and any use of the disclosed products and methods. More particularly, this invention contemplates any use of such rare-cutting endonuclease for genetic engineering and gene therapy.
  • Meganucleases constitute a family of very rare-cutting endonucleases. It was first characterised at the beginning of the Nineties by the use (in vivo) of the protein I-Sce I (Omega nuclease, originally encoded by a mitochondrial group I intron of the yeast Saccharomyces cerevisia ). Homing endonucleases encoded by introns ORF, independent genes or intervening sequences (inteins) are defined now as “meganucleases”, with striking structural and functional properties that distinguish them from “classical” restriction enzymes (generally from bacterial system R/MII).
  • these nucleases By making a site-specific double-strand break in the intronless or inteinless alleles, these nucleases create recombinogenic ends, which engage in a gene conversion process that duplicates the coding sequence and leads to the insertion of an intron or an intervening sequence at the DNA level.
  • Meganucleases fall into 4 separated families on the basis of pretty well conserved amino acids motifs. One of them is the dodecapeptide family (dodecamer, DOD, D1-D2, LAGLI-DADG, P1-P2). This is the largest family of proteins clustered by their most general conserved sequence motif: one or two copies (vast majority) of a twelve-residue sequence: the di-dodecapeptide. Meganucleases with one dodecapetide (D) are around 20 kDa in molecular mass and act as homodimer.
  • D dodecapetide
  • I-Ceu I, and I-Cre I illustrate the meganucleases with one Dodecapeptide motif (mono-dodecapeptide).
  • I-Dmo I, I-Sce I, PI-Pfu I and PI-Sce I illustrate meganucleases with two Dodecapeptide motifs.
  • Endonucleases are requisite enzymes for today's advanced gene engineering techniques, notably for cloning and analyzing genes. Meganucleases are very interesting as rare-cutter endonucleases because they have a very low recognition and cleavage frequency in large genome due to the size of their recognition site. Therefore, the meganucleases are used for molecular biology and for genetic engineering, more particularly according to the methods described in WO 96/14408, U.S. Pat. No. 5,830,729, WO 00/46385, and WO 00/46386.
  • the invention concerns a hybrid meganuclease comprising a first domain and a second domain, said first and second domains being derived from two different initial LAGLIDADG meganucleases, said initial meganucleases being either mono- or di-LAGLIDADG meganucleases.
  • the invention also contemplates a hybrid meganuclease comprising two domains, each domain being derived from the same meganuclease and said two domains having a different arrangement than the initial meganuclease (i.e. the second domain is derived from the N-terminal domain of the initial meganuclease and/or the first domain is derived from the C-terminal of the initial meganuclease).
  • the invention also concerns a single-chain meganuclease comprising a first domain and a second domain, said first and second domains being derived from an initial mono-LAGLIDADG meganuclease.
  • the invention further concerns any polynucleotide encoding a hybrid or single-chain meganuclease according to the present invention and vectors, cells or non-human animals comprising such a polynucleotide.
  • the invention concerns any use of a hybrid or single-chain meganuclease according to the present invention or a polynucleotide encoding it for molecular biology, genetic engineering and gene therapy.
  • FIG. 1 is a ribbon representation of I-DmoI (pdb code 1b24).
  • the discontinuous line represents the two-fold pseudo-symmetry axis between the two domains.
  • the N-terminal domain of I-DmoI is left of that axis, and the C-terminal domain is on the right side.
  • DNA (not present in structure 1b24) should bind perpendicular to the symmetry axis below the two ⁇ -sheets (arrows).
  • ⁇ D and ⁇ ′ D refer to helices comprising the dodecapeptide motif, DBM to DNA binding moiety, and V to variable sequence.
  • FIG. 2 is a ribbon representation of dimeric I-CreI with bound DNA in stick representation (pdb code 1g9y).
  • the discontinuous line represents the two-fold symmetry axis between the two domains or monomers.
  • the bound DNA lies perpendicular to the symmetry axis below the two ⁇ -sheets (arrows).
  • ⁇ D refers to helix comprising the dodecapeptide motif, DBM to DNA binding moiety, and V to variable sequence.
  • FIGS. 3A and 3B respectively are ribbon representations of I-DmoI and I-CreI in the region of the dodecapeptide motifs.
  • the main chain atoms of residues corresponding to the dodecapeptide motifs are shown in stick representation, together with the superimposed atoms from the other protein.
  • the discontinuous line represents the two-fold symmetry axis between the two protein domains.
  • Stars represent, in FIG. 3A , the limits of the linkers between the I-DmoI domains and in FIG. 3B the corresponding positions in I-CreI where that linker is to be engineered. Orientations of the proteins are as in FIGS. 1 and 2 .
  • FIG. 4 is a ribbon representation of the I-DmoI/I-CreI hybrid protein (model structure built by juxtaposition of the two domains taken from their respective X-ray structures).
  • the linker joining both domains, which is the end of the I-DmoI part, is between the two stars.
  • the discontinuous line represents the two-fold symmetry axis between the two protein domains.
  • the N-term domain of I-DmoI is left and the I-CreI domain right of the axis.
  • ⁇ D and ⁇ ′ D refer to helices comprising the dodecapeptide motif, DBM to DNA binding moiety, and V to variable sequence.
  • FIGS. 5A and 5B respectively are ribbon representations of the I-CreI dimer (1g9y) and the single chain I-CreI (modelled structure).
  • FIG. 5A The stars indicate where the linker is to be introduced; three ⁇ -helices in the first monomer (following the left-most star) are removed in the single chain, together with the N-terminal residues of the second monomer (prior to the other star).
  • FIG. 5B The loop joining both domains, comprised between the two stars, is taken from I-DmoI (structure 1b24).
  • the grey disk represent the symmetry axis (orientation is from the top of the structures, e.g. cpmpared to the previous figures, it was rotated by 90° around an horizontal axis).
  • FIGS. 6A and 6B disclose the amino acid sequence of two alternatives of hybrid meganuclease I-Dmo I/I-Cre I and a polynucleotide sequence encoding each alternative. Underlined residues are the LAGLI-DADG motifs. In bold, residues within the I-DmoI domain that are mutated are shown. The “H” indicates the swap point, at the boundary between the I-DmoI and I-CreI domains. In all protein sequences, the two first N-terminal residues are methionine and alanine (MA), and the three C-terminal residues alanine, alanine and aspartic acid (AAD).
  • MA methionine and alanine
  • AAD aspartic acid
  • FIG. 7 discloses the amino acid sequence of an alternative of a single chain I-Cre I and one polynucleotide encoding said single chain meganuclease.
  • the two first N-terminal residues are methionine and alanine (MA), and the three C-terminal residues alanine, alanine and aspartic acid (AAD).
  • MA methionine and alanine
  • AAD aspartic acid
  • FIG. 8 shows the In vitro cleavage assay for the hybrid meganuclease I-Dmo I/I-Cre I ( FIG. 8B ) and the SDS-PAGE gel with such hybrid ( FIG. 8A ).
  • FIG. 8A Line A: molecular weight markers; Line B: Hybrid meganuclease I-Dmo I/I-Cre I; Line C: Wild type meganuclease I-Dmo I.
  • FIG. 8A Line A: molecular weight markers
  • Line B Hybrid meganuclease I-Dmo I/I-Cre I
  • Line C Wild type meganuclease I-Dmo I.
  • FIG. 9 shows the In vitro cleavage assay for the single chain meganuclease I-Cre I ( FIG. 9B ) and the SDS-PAGE gel of the gel filtration with such single chain meganuclease ( FIG. 9A ).
  • FIG. 9A Line A: molecular weight markers; Lines B and C: dead colume of gel filtration. Line D: single chain meganuclease I-Cre I.
  • FIG. 10A is a schematic representation of the LACURAZ reporter contruct.
  • LACZ represents the elements of the Lac Z gene. The sections A of each side of the intervening sequence comprise the internal duplication of the Lac Z gene.
  • pADH1 is a yeast constitutive promoter.
  • tADH1 is a yeast terminator.
  • Ura3 represents the Ura3 gene. The arrows represent the transcription beginning.
  • the tag “Cleavage site” refers to the recognition and cleavage site of the assayed meganuclease.
  • Trp1 refers to a Trp1 selectable marker and ⁇ cen>> to an ARS-CEN origin of replication.
  • FIG. 10B is a schematic representation of the meganuclease inducible expression vector.
  • pGAL10 is a yeast promoter which is inducible in presence of galactose.
  • tADH1 is a yeast terminator.
  • Leu2 and “2 ⁇ ” respectively refer to a Leu2 selectable marker and a 2 ⁇ origin of replication. The arrow represents the transcription beginning.
  • FIG. 11 shows the combinations of co-transformations and subsequent modifications of the reporter gene.
  • ⁇ # X>> refers to the combination disclosed in Table A.
  • the light grey boxes refer to Ura3 gene.
  • the dark grey boxes refer to the Lac Z gene.
  • the white boxes refer to the gene encoding the meganuclease.
  • the white tags refer to the recognition and cleavage site of the assayed meganuclease.
  • “meganuclease” is intended a rare-cutting endonuclease, typically having a polynucleotide recognition site of about 12-40 bp in length, more preferably of 14-40 bp.
  • Typical meganucleases cause cleavage inside their recognition site, leaving 4 nt staggered cut with 3′OH overhangs.
  • the meganuclease are also commonly called homing endonuclease.
  • “meganucleases” according to the present invention belong to the dodecapeptide family (LAGLIDADG).
  • LAGLIDADG meganucleases are listed in Table 1.
  • helix or “helices” is intended in the present invention ⁇ -helix or ⁇ -helices.
  • ⁇ D and a LHGLIDADG in the present invention refers to the helix comprising the LAGLIDADG, DOD or dodecapeptide motif.
  • derived is intended that the domain comprises the sequence of a domain of the meganuclease from which the domain is derived. Said sequence of a domain can comprise some modifications or substitutions.
  • a “target site” or recognition and/or cleavage site as used herein, refers to a polynucleotide sequence bound and cleaved by a meganuclease.
  • recombinant polypeptide is used herein to refer to polypeptides that have been artificially designed and which comprise at least two polypeptide sequences that are not found as contiguous polypeptide sequences in their initial natural environment, or to polypeptides which have been expressed from a recombinant polynucleotide.
  • mammals as well as other animals (e.g., birds, fish, reptiles, insects).
  • mammals e.g., birds, fish, reptiles, insects.
  • mammal and mammalian refer to any vertebrate animal, including monotremes, marsupials and placental, that suckle their young and either give birth to living young (eutharian or placental mammals) or are egg-laying (metatharian or nonplacental mammals).
  • mammalian species include humans and other primates (e.g., monkeys, chimpanzees), rodents (e.g., rats, mice, guinea pigs) and ruminents (e.g., cows, pigs, horses).
  • primates e.g., monkeys, chimpanzees
  • rodents e.g., rats, mice, guinea pigs
  • ruminents e.g., cows, pigs, horses.
  • reporter gene refers to a nucleic acid sequence whose product can be easily assayed, for example, calorimetrically as an enzymatic reaction product, such as the lacZ gene which encodes for—galactosidase.
  • reporter molecules include enzymes such as ⁇ -galactosidase, ⁇ -glucoronidase, ⁇ -glucosidase; luminescent molecules such as green flourescent protein and firefly luciferase; and auxotrophic markers such as His3p and Ura3p. (See, e.g., Chapter 9 in Ausubel, F. M., et al. Current Protocols in Molecular Biology, John Wiley & Sons, Inc. (1998)).
  • nucleic acid As used interchangeably herein, the terms “nucleic acid” “oligonucleotide”, and “polynucleotide” include RNA, DNA, or RNA/DNA hybrid sequences of more than one nucleotide in either single chain or duplex form.
  • polynucleotide refers to a polymer of units comprising a purine or pyrimidine, a ribose or deoxyribose sugar moiety, and a phosphate group, or phosphodiester linkage.
  • polynucleotides also refers to polynucleotide comprising “modified nucleotides” which comprise at least one of the following modifications (a) an alternative linking group, (b) an analogous form of purine, (c) an analogous form of pyrimidine, or (d) an analogous sugar.
  • Endonuclease is intended an enzyme capable of causing a double-stranded break in a DNA molecule at highly specific locations.
  • Cells or “host cells”, are terms used interchangeably herein. It is understood that such terms refer not only to the particular subject cell but to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not be identical to the parent cell, but are still included within the scope of the term as used herein.
  • Identity refers to sequence identity between two nucleic acid molecules or polypeptides. Identity can be determined by comparing a position in each sequence which may be aligned for purposes of comparison. When a position in the compared sequence is occupied by the same base, then the molecules are identical at that position. A degree of similarity or identity between nucleic acid or amino acid sequences is a function of the number of identical or matching nucleotides at positions shared by the nucleic acid sequences. Various alignment algorithms and/or programs may be used to calculate the identity between two sequences, including FASTA, or BLAST which are available as a part of the GCG sequence analysis package (University of Wisconsin, Madison, Wis.), and can be used with, e.g., default settings.
  • non-human animals include mammalians such as rodents, non-human primates, sheep, dog, cow, chickens, amphibians, reptiles, etc.
  • Preferred non-human animals are selected from the rodent family including rat and mouse, most preferably mouse, though transgenic amphibians, such as members of the Xenopus genus, and transgenic chickens, cow, sheep can also provide important tools.
  • vector refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked.
  • One type of preferred vector is an episome, i.e., a nucleic acid capable of extrachromosomal replication.
  • Preferred vectors are those capable of autonomous replication and/or expression of nucleic acids to which they are linked.
  • Vectors capable of directing the expression of genes to which they are operatively linked are referred to herein as “expression vectors”.
  • a vector according to the present invention comprises, but is not limited to, a YAC (yeast artificial chromosome), a BAC (bacterial artificial), a baculovirus vector, a phage, a phagemid, a cosmid, a viral vector, a plasmid, a RNA vector or a linear or circular DNA or RNA molecule which may consist of a chromosomal, non chromosomal, semi-synthetic or synthetic DNA.
  • expression vectors of utility in recombinant DNA techniques are often in the form of “plasmids” which refer generally to circular double stranded DNA loops which, in their vector form are not bound to the chromosome.
  • Suitable vectors are known to those of skill in the art and commercially available, such as the following bacterial vectors: pQE70, pQE60. pQE-9 (Qiagen), pbs, pD1O, phagescript, psiX174. pbluescript SK. pbsks. pNH8A. pNH16A, pNH18A, pNH46A (Stratagene); ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 (Pharmacia); pWLNEO. pSV2CAT, pOG44, pXT1, pSG (Stratagene); pSVK3, pBPV, pMSG, pSVL (Pharmacia); pQE-30 (QIAexpress).
  • Viral vectors include retrovirus, adenovirus, parvovirus (e.g., adenoassociated viruses), coronavirus, negative strand RNA viruses such as orthomyxovirus (e.g., influenza virus), rhabdovirus (e.g., rabies and vesicular stomatitis virus), paramyxovirus (e.g.
  • RNA viruses such as picomavirus and alphavirus
  • double stranded DNA viruses including adenovirus, herpesvirus (e.g., Herpes Simplex virus types 1 and 2, Epstein-Barr virus, cytomegalovirus), and poxvirus (e.g., vaccinia, fowlpox and canarypox).
  • herpesvirus e.g., Herpes Simplex virus types 1 and 2, Epstein-Barr virus, cytomegalovirus
  • poxvirus e.g., vaccinia, fowlpox and canarypox
  • Other viruses include Norwalk virus, togavirus, flavivirus, reoviruses, papovavirus, hepadnavirus, and hepatitis virus, for example.
  • retroviruses examples include: avian leukosis-sarcoma, mammalian C-type, B-type viruses, Dtype viruses, HTLV-BLV group, lentivirus, spumavirus (Coffin, J. M., Retroviridae: The viruses and their replication, In Fundamental Virology, Third Edition, B. N. Fields, et al., Eds., Lippincott-Raven Publishers, Philadelphia, 1996).
  • murine leukemia viruses include murine leukemia viruses, murine sarcoma viruses, mouse mammary tumor virus, bovine leukemia virus, feline leukemia virus, feline sarcoma virus, avian leukemia virus, human T-cell leukemia virus, baboon endogenous virus, Gibbon ape leukemia virus, Mason Pfizer monkey virus, simian immunodeficiency virus, simian sarcoma virus, Rous sarcoma virus and lentiviruses.
  • vectors are described, for example, in McVey et al., U.S. Pat. No. 5,801,030, the teachings of which are incorporated herein by reference.
  • Vectors can comprise selectable markers (for example, neomycin phosphotransferase, histidinol dehydrogenase, dihydrofolate reductase, hygromycin phosphotransferase, herpes simplex virus thymidine kinase, adenosine deaminase, glutamine synthetase, and hypoxantiein-guanine phosphoribosyl transferase for eukaryotic cell culture; TRP1 for S. cerevisiae ; tetracycline, rifampicin or ampicillin resistance in E. coli ; etc. . . . ).
  • selectable markers for example, neomycin phosphotransferase, histidinol dehydrogenase, dihydrofolate reductase, hygromycin phosphotransferase, herpes simplex virus thymidine kinase, aden
  • a polynucleotide to be linearized or excised is flanked by a cleavage site if such a site is present at or near either or both ends of the polynucleotide.
  • Near is preferably intended in the present invention that the cleavage site is located at less than 1 kb, preferably less than 500 bp, more preferably less than 200, or 100 bp, of the end of the polynucleotide to be integrated.
  • the present invention relates to new designed rare-cutting endonucleases and use thereof.
  • These new designed rare-cutting endonucleases are preferably derived from the meganuclease family of “dodecapeptide” LAGLIDADG.
  • Meganucleases form a class of over 200 rare-cutting double-stranded DNA endonucleases (group I intron homing endonucleases and inteins) (Belfort and Roberts, 1997, Nucleic Acids Res, 25, 3379-3388; Jurica and Stoddard, 1999, Cell Mol Life Sci, 55, 1304-1326). They recognize asymmetrical DNA sequences that are between 14 and 40 base pairs in length, producing double-strand breaks at about the center of their target sequence. Said target site is defined herein as the sum of two different half-sites.
  • 16 (and over) nucleotides-long DNA sequences can be expected to be unique, even in a genome the size of the human genome (3 ⁇ 10 9 base pairs). Meganucleases will thus cut cellular genomes only once, at the target locus.
  • the LAGLIDADG protein family is characterized by the presence of one or two copies of a well-conserved sequence motif, termed dodecapeptide, or P1 and P2, LAGLI and DADG or LAGLIDADG. Outside of those motifs, there is no relevant sequence homology (overall pairwise sequence homologies are below 25%).
  • dodecapeptide or P1 and P2
  • LAGLI and DADG or LAGLIDADG outside of those motifs, there is no relevant sequence homology (overall pairwise sequence homologies are below 25%).
  • the smaller examples i.e. I-CreI (Durrenberger and Rochaix, 1991, Embo J, 10, 3495-3501), have only one dodecapeptide motif and function as homodrimers of two 15-20 kDa subunits or domains. These proteins having only one dodecapeptide motif are called in the present application as “mono-dodecapeptide” proteins. Larger proteins, i.e.
  • I-DmoI (Dalgaard et al., 1993, Proc Natl Acad Sci USA, 90, 5414-5417), I-SceI (Jacquier et Dujon, 1985, Cell, 41, 383-394) and PI-SceI (Gimble and Wang, 1996, J Mol Biol, 263, 163-180), on the other hand, are single-chain proteins (20-30 kDa) bearing two (non-identical) dodecapeptide motifs. These proteins having two dodecapeptide motifs are called in the present application as “di-dodecapeptide” proteins.
  • each domain presents a DNA binding interface that drives the protein towards interacting with one of the two half sites of the target DNA sequence.
  • a unique catalytic, active site comprises amino acid residues from both structural domains, whose specific nature and spatial distribution is required for DNA cleavage.
  • the residues in the active sites are divergent.
  • the only residues that display persistent conservation are the last acidic amino acids (D or E) from both LAGLIDADG motifs (underlined residue). Therefore, it is difficult to assign functional roles to residues in the active site, except for those acidic amino acids. Mutations of those residues abolish catalysis, but not DNA binding (Lykke-Andersen et al., 1997, Embo J, 16, 3272-3281; Gimble & Stephens, 1995, J. Biol. Chem., 270, 5849-5856).
  • a hydration shell consisting of several water molecules structurally organized by the amino acid side chains of acidic and basic residues, together with divalent cations, has probably an essential role in conducting the cleavage of DNA phosphodiester bonds (Chevalier et al., 2001, Nat Struct Biol, 8, 312-316).
  • the present invention shows that LAGLIDADG endonucleases are modular and that domain swapping of natural homing endonucleases or meganucleases is both possible and fruitful: novel, artificial combinations of two domains taken from different LAGLIDADG meganucleases recognize, bind and cut DNA sequences made of the corresponding two half-sites.
  • Engineering such artificial combinations is primarily useful in order to generate meganucleases with new specificity.
  • the LAGLIDADG protein family essentially shows a sequence conservation in the dodecapeptide motifs.
  • the 3D structure are similar: they have the same set of secondary structure elements organized with a unique topology. Conservation of the dodecapeptide motif and protein size (in particular, the separation distance in sequence length between two dodecapeptide motifs in di-dodecameganuclease together with the biological relationships, i.e. same “function” and conserved 3D architecture) are thought sufficient to propose that the secondary structure is conserved.
  • the present invention concerns the novel endonucleases, more particularly hybrid meganucleases, preferably derived from at least two different LAGLIDADG meganucleases.
  • the initial meganucleases can be “mono-dodecapeptide” or “mono-LAGLIDADG”, such as I-Cre I meganuclease, or “di-dodecapeptide” or “di-LAGLIDADG” meganucleases such as I-Dmo I.
  • These new designed endonucleases or meganucleases are hybrid of LAGLIDADG meganucleases.
  • the invention concerns a hybrid meganuclease comprising two domains, each domain being derived from a different LAGLIDADG meganuclease. See Table 1 (Motif “D” refers to mono-dodecapeptide meganucleases and motif “dd” or “DD” to di-dodecapeptide meganucleases).
  • the invention also contemplates a hybrid meganuclease comprising two domains, each domain being derived from the same meganuclease but in a different arrangement (e.g., location, organization, position, etc.) as compared to the initial meganuclease (e.g., the second domain is derived from the N-terminal domain of the initial meganuclease and/or the first domain is derived from the C-terminal of the initial meganuclease).
  • a hybrid meganuclease comprising two domains, each domain being derived from the same meganuclease but in a different arrangement (e.g., location, organization, position, etc.) as compared to the initial meganuclease (e.g., the second domain is derived from the N-terminal domain of the initial meganuclease and/or the first domain is derived from the C-terminal of the initial meganuclease).
  • domain of LAGLIDADG meganucleases is intended in the present invention a polypeptide fragment comprising or consisting of a dodecapeptide motif and a DNA binding moiety.
  • the domain can also comprise additional polypeptide sequences not involved in the DNA binding nor in the domain interface. However, those additional sequences have variable size and are generally not critical for the DNA recognition and binding nor the endonuclease activity.
  • the dodecapeptide motif is involved in an ⁇ -helix, herein schematically called ⁇ LAGUDADG or ⁇ D .
  • the DNA binding moiety herein schematically called DBM, generally comprises ⁇ -helices and ⁇ -strands.
  • the minimal DNA binding moiety in a meganuclease is a ⁇ -hairpin (2 ⁇ -stands connected by a loop or turn).
  • Natural meganucleases comprise two such ⁇ -hairpins in each DNA binding moiety, connecting into a 4-stranded ⁇ -sheet. The connecting between the two 1-hairpins comprises an ⁇ -helix.
  • the DNA binding moiety generally comprises a further ⁇ -helix dowstream of the 4-stranded ⁇ -sheet.
  • the additional polypeptide sequences could be found at each side of the group consisting of the dodecapeptide motif and the DNA binding moiety. Therefore, a meganuclease domain according to the present invention comprises the helix comprising the dodecapeptide motif, ⁇ D , and a DNA binding moiety, DBM.
  • an additional sequence can be further comprised in said domain. Said additional sequence is possible at the N-terminal side of a first domain of the hybrid meganuclease or at the C-terminal side of a second domain of the hybrid meganuclease.
  • the LAGLIDADG meganucleases comprising two dodecapeptide motifs comprise two domains, one domain called N-terminal domain and the other C-terminal domain.
  • the N-terminal domain consecutively comprises an additional optional sequence, the dodecapeptide motif and the DNA binding moiety.
  • the C-terminal domain consecutively comprises the dodecapeptide motif, the DNA binding moiety and an additional optional sequence.
  • the two dodecapeptide ⁇ -helices of each domain form a tightly packed domain interface.
  • the loop connecting the two domains is between the DNA binding moiety of the N-terminal domain and the helix comprising the second dodecapeptide motif of the C-terminal domain.
  • the di-dodecapeptide meganucleases could schematically be represented by the following structure from the N-terminal end to the C-terminal end: V ⁇ D DBM (L) ⁇ ′ D DBM′ V′ (V refering to additional optional sequence, ⁇ D to the helix comprising the dodecapeptide motif, DBM to the DNA binding moiety, L to the connecting loop; the ′ refers to the elements of the C-terminal domain).
  • the helices ⁇ D and ⁇ ′ D correspond to the helices comprising the dodecapeptide motifs.
  • the domains of a meganuclease comprising two dodecapeptide motifs are asymmetric (similar but generally not identical).
  • the dimeric LAGLIDADG meganucleases comprising one dodecapeptide motif herein called mono-dodecapeptide meganucleases, consecutively comprises an additional optional polypeptide sequence, the dodecapeptide motif, the DNA binding moiety, and an additional optional polypeptide sequence.
  • the two dodecapeptide helices (one in each monomer) form a tightly packed dimer interface.
  • the mono-dodecapeptide meganucleases could schematically be represented by the following structure comprising from the N-terminal end to the C-terminal end: V ⁇ D DBM V′ (V and V′ refering to additional optional sequences, ⁇ D to the helix comprising the dodecapeptide motif, DBM to the DNA binding moiety). Number of mono-dodecapeptide meganucleases are known. See Table 1, Motif D (Also see Lucas et al., 2001, Nucleic Acids Res., 29, 960-9, Table 1 and FIG. 1
  • the invention concerns a hybrid meganuclease comprising or consisting of a first domain and a second domain in the orientation N-terminal toward C-terminal, said first and second domains being derived from two different initial LAGLIDADG meganucleases, said initial meganucleases being either mono- or di-dodecapeptide meganucleases and said first and second domains being bound by a convenient linker and wherein said hybrid meganuclease is capable of causing DNA cleavage.
  • the invention also contemplates a hybrid meganuclease comprising or consisting of two domains, each domain being derived from the same meganuclease, said two domains having a different arrangement than the initial meganuclease (i.e. the second domain is derived from the N-terminal domain of the initial meganuclease and/or the first domain is derived from the C-terminal of the initial meganuclease) and said first and second domains being bound by a convenient linker.
  • the initial mono- and di-dodecapeptide meganucleases according to the present invention for the generation of hybrid meganucleases are preferably selected from the group consisting of the meganucleases listed in the Table 1, notably I-Sce I, I-Chu I, I-Dmo I, I-Cre I, I-Csm I, PI-Sce I, PI-Tli I, PI-Mtu I, I-Ceu I, I-Sce II, I-Sce III, HO, PI-Civ I, PI-Ctr I, PI-Aae I, PI-Bsu I, PI-Dha I, PI-Dra I, PI-Mav I, PI-Mch I, PI-Mfu I, PI-Mfl I, PI-Mga I, PI-Mgo I, PI-Min I, PI-Mka I, PI-Mle I, PI-Mma
  • the initial di-dodecapeptide meganucleases according to the present invention for the generation of hybrid meganuclease are preferably selected from the group consisting of the meganucleases comprising a “DD” or “dd” motif listed in the Table 1, notably: I-Sce I, I-Chu I, I-Dmo I, I-Csm I, PI-Sce I, PI-Tli I, PI-Mtu I, I-Sce II, I-Sce III, HO, PI-Civ I, PI-Ctr I, PI-Aae I, PI-Bsu I, PI-Dha I, PI-Dra I, PI-Mav I, PI-Mch I, PI-Mfu I, PI-Mfl I, PI-Mga I, PI-Mgo I, PI-Min I, PI-Mka I, PI-Mle I, PI-Mma I
  • the initial mono-dodecapeptide meganucleases according to the present invention for the generation of hybrid meganucleases are preferably selected from the group consisting of the meganucleases comprising a “D” motif listed in the Table 1, notably: I-Cre I, I-Ceu I; preferably, I-Cre I.
  • the present invention concerns the hybrid meganuclease comprising or consisting of a first domain from a mono- or di-dodecapeptide meganuclease and a second domain from another mono- or di-dodecapeptide meganuclease, said first and second domains being bound by a convenient linker.
  • the invention concerns a hybrid meganuclease selected from the group consisting of the following hybrid meganucleases:
  • I-Dmo I/I-Cre I, and I-Cre I/I-Dmo I are preferably preferably I-Dmo I/I-Cre I, and I-Cre I/I-Dmo I; or,
  • I-Dmo I/I-Cre I More preferably the hybrid meganuclease of SEQ ID No 2 or 4.
  • the first indicated meganuclease corresponds to the origin of the first domain of the hybrid meganuclease and the second indicated meganuclease to the origin of the second domain of the hybrid meganuclease.
  • said hybrid meganuclease comprises or consists of:
  • said hybrid meganuclease comprises or consists of:
  • said hybrid meganucleases comprise or consists of a first domain from a di-dodecapeptide meganuclease and a second domain from another di-dodecapeptide meganuclease, said first and second domains being bound by a convenient linker.
  • said hybrid meganuclease comprises or consists of:
  • said hybrid meganuclease comprises or consists of:
  • said hybrid meganuclease comprises or consists of:
  • hybrid meganucleases comprising or consisting of a first domain and a second domain from the same di-dodecapeptide meganuclease, said first and second domains being bound by a convenient linker, if the ordering of the domain is not the same of the initial meganuclease. More particularly, are contemplated in the present invention the hybrid meganuclease comprising a first and a second domains in the orientation N-terminal toward C-terminal, wherein each domain are derived from the same di-dodecapeptide meganuclease and said first domain is derived from the C-terminal domain and said second domain is derived from the N-terminal domain.
  • the means for introducing a link between the two domains of the hybrid meganuclease is well known by one man skilled in the art.
  • the preferred means are either the use of a flexible polypeptide linker or the use of a loop from a di-dodecapeptide meganuclease.
  • the loop is an embodiment of the linker.
  • the flexible polypeptide linker essentially comprises glycine, serine and threonine residues.
  • the loop can be either a loop present in one of the 2 initial di-dodecapeptide meganucleases used for design the hybrid meganuclease or a loop from any other di-dodecapeptide meganuclease, preferably the I-Dmo I loop, which is introduced between the two domains.
  • a first preferred embodiment concerns a hybrid meganuclease comprising or consisting of a first domain derived from the N-terminal domain of a di-dodecapeptide meganuclease (A) and a second domain derived from the C-terminal domain of another di-dodecapeptide meganuclease (B), said first and second domains being bound by a convenient linker.
  • the swapping point is positioned at any convenient place. The swapping point is the point at which the sequence of the first meganuclease (A) is substantially replaced by the sequence of the second meganuclease (B).
  • This swapping point can be positioned from the last helix of the DNA binding moiety DBM to the end of the helix comprising the second dodecapeptide motif, ⁇ ′ D . It is preferably positioned within the loop (L) preceding the second dodecapeptide motif ( ⁇ ′ D ) or in the helix ( ⁇ ′ D ) comprising the dodecapeptide motif. Generally, few amino acids, about 4 to 10 amino acids, upstream the dodecapeptide motif, also participate to the formation of the helix ( ⁇ ′ D ). In one preferred embodiment, the swapping point is positioned within the helix ( ⁇ ′ D ).
  • the swapping point is positioned in the helix ( ⁇ ′ D ) before the dodecapeptide motif itself
  • the resulting hybrid meganuclease comprises the N-terminal domain of the meganuclease A and the C-terminal domain of the meganuclease B.
  • Such hybrid meganuclease schematically comprises: V V′ Type optional ⁇ D DBM L ⁇ ′ D DBM′ optional 1 A ⁇ A A(N) A ⁇ ′A B(C) B 2 A ⁇ A A(N) A ⁇ ′A/ ⁇ ′B B(C) B 3 A ⁇ A A(N) A ⁇ ′B B(C) B 4 A ⁇ A A(N) A/B ⁇ ′B B(C) B 5 A ⁇ A A(N) B ⁇ ′B B(C) B 6 A ⁇ A A(N)/B(N) B ⁇ ′B B(C) B A and B indicating the meganuclease at the origin of the segment V, ⁇ D , DBM, L, ⁇ ′ D , DBM′, V′.
  • A/B indicates that the swapping point is into the segment, the origin of the first part of the element is A and that of the second part is B.
  • ⁇ A and ⁇ B refer to the ⁇ D of the N-terminal domain and ⁇ ′A and ⁇ ′B refer to the ⁇ ′ D of the C-terminal domain.
  • DBM bitmap
  • the swapping point is replaced by a “swapping domain”.
  • the helices ⁇ D and ⁇ ′ D of the hybrid meganuclease can be a mixture of the two initial meganucleases.
  • the amino acid residues from the helices ⁇ D and ⁇ ′ D which are directed towards the helices interface are those of one meganuclease for both helices ⁇ D and ⁇ ′ D (either those of ⁇ D and ⁇ ′ D from the meganuclease A or those of ⁇ D and ⁇ ′ D from the meganuclease B).
  • the residues at the interface could be derived from another pair of dodecapeptide helices from a mono- or di-dodecapeptide meganuclease X.
  • the amino acid residues from the helix comprising ⁇ D and ⁇ ′ D which are directed towards the inside of the domain are those corresponding to the residues found at that position in that domain of the meganuclease it comes from (those of ⁇ D from the meganuclease A and those of ⁇ ′ D from the meganuclease B).
  • Such hybrid meganuclease schematically comprises: ⁇ D ⁇ ′ D Type V optional intra inter DBM L inter intra DBM′ V′ optional 1 A ⁇ A ⁇ A A(N) A ⁇ ′A ⁇ ′B B(C) B 2 A ⁇ A ⁇ B A(N) A ⁇ ′B ⁇ ′B B(C) B 3 A ⁇ A ⁇ X A(N) A ⁇ ′X ⁇ ′B B(C) B 4 A ⁇ A ⁇ X A(N) A ⁇ X ⁇ ′B B(C) B 5 A ⁇ A ⁇ A A(N) A/B ⁇ ′A ⁇ ′B B(C) B 6 A ⁇ A ⁇ B A(N) A/B ⁇ ′B ⁇ ′B B(C) B 7 A ⁇ A ⁇ X A(N) A/B ⁇ ′X ⁇ ′B B(C) B 8 A ⁇ A ⁇ X A(N) A/B ⁇ X ⁇ ′B B(C) B 9 A ⁇
  • A/B indicates that the swapping point is into the segment, the origin of the first part of the element is A and that of the second part is B.
  • “inter” refers to the residues of ⁇ D and ⁇ ′ D towards the interface between the domains, and “intra” refers to the residues of ⁇ D and ⁇ ′ D towards the inside of each domain.
  • ⁇ A and ⁇ B refer to the ⁇ D of the N-terminal domain and ⁇ ′A and ⁇ ′B refer to the ⁇ ′ D of the C-terminal domain.
  • DBM column, the letter (N) and (C), respectively, indicate the origin from the N-terminal domain and the C-terminal domain.
  • the loop can be completely or partially replaced by a convenient linker.
  • a convenient linker is preferably flexible.
  • Said flexible linker preferably comprises glycine, serine and threonine residues.
  • Short flexible linker can also be introduced between the loop and the domains.
  • the loop can also be replaced by a loop from any other di-dodecapeptide meganuclease, preferably the I-Dmo I loop.
  • such hybrid meganuclease comprising or consisting of a first domain from the N-terminal domain of a di-dodecapeptide meganuclease (A) and a second domain from the C-terminal domain of another di-dodecapeptide meganuclease (B), said first and second domains being bound by a convenient linker, can further comprise, at its N and/or C-terminal end, a loop or linker and any additional domain.
  • said additional domain is a DNA binding domain, a transcription activator or repressor domain, a nuclear localization signal, or a DNA cleavage domain.
  • the endonuclease activity of such hybrid can be abolished.
  • the main function of hybrid is a specific DNA binding.
  • a second embodiment concerns a hybrid meganuclease comprising or consisting of a first domain derived from the N-terminal domain of a di-dodecapeptide meganuclease (A) and a second domain derived from the N-terminal domain of another di-dodecapeptide meganuclease (B), said first and second domains being bound by a convenient linker.
  • the swapping point is positioned at any convenient place. It is preferably positioned at the end of the loop (LA) preceding the second dodecapeptide motif ( ⁇ ′ D ) or in the helix ( ⁇ ′ D ). In one preferred embodiment, the swapping point is positioned within the helix ( ⁇ ′ D ).
  • the swapping point is positioned in the helix ( ⁇ ′ D ) before the dodecapeptide motif itself.
  • the resulting hybrid meganuclease comprises, from the N-terminal end to C-terminal end, the N-terminal domain of the meganuclease A and the N-terminal domain of the meganuclease B.
  • the resulting hybrid meganuclease does not comprise the DBM of the C-terminal domain of the meganuclease B, more preferably its C-terminal domain.
  • Such hybrid meganuclease schematically comprises: Type V optional ⁇ D DBM L ⁇ ′ D DBM′ V′ optional 1 A ⁇ A A(N) A ⁇ ′A B(N) B 2 A ⁇ A A(N) A ⁇ ′A/ ⁇ B B(N) B 3 A ⁇ A A(N) A ⁇ B B(N) B A and B indicating the meganuclease at the origin of the segment V, ⁇ D , DBM, L, ⁇ ′ D , DBM′, V′.
  • A/B indicates that the swapping point is into the segment, the origin of the first part of the element is A and that of the second part is B.
  • ⁇ A and ⁇ B refer to the ⁇ D of the N-terminal domain and ⁇ ′A and ⁇ ′B refer to the ⁇ ′ D of the C-terminal domain.
  • DBM DBM
  • N and C respectively, indicate the origin from the N-terminal domain and the C-terminal domain.
  • the swapping point is replaced by a swapping domain.
  • the helices ⁇ D and ⁇ ′ D of the hybrid meganuclease can be a mixture of the two initial meganucleases.
  • the amino acid residues from the helices ⁇ D and ⁇ ′ D which are directed towards the helix interface are those of one meganuclease for both helices ⁇ D and ⁇ ′ D (those of ⁇ D and ⁇ ′ D from either the meganuclease A or B).
  • the residues at the interface could be derived from another pair of dodecapeptide helices from a mono- or di-dodecapeptide meganuclease X.
  • amino acid residues from the helices ⁇ D and ⁇ ′ D which are directed towards the inside of the domain are those corresponding to the residues found at that position in that domain of the meganuclease it comes from (those of ⁇ D from the meganuclease A and those of ⁇ D from the meganuclease B).
  • Such hybrid meganuclease schematically comprises: V op- ⁇ D ⁇ ′ D V′,op- Type tional intra inter DBM L inter intra DBM′ tional 1 A ⁇ A ⁇ A A(N) A ⁇ ′A ⁇ B B(N) B 2 A ⁇ A ⁇ B A(N) A ⁇ ′B ⁇ B B(N) B 3 A ⁇ A ⁇ X A(N) A ⁇ ′X ⁇ B B(N) B 4 A ⁇ A ⁇ X A(N) A ⁇ X ⁇ B B(N) B A, B, and X indicating the meganuclease at the origin of the segment V, ⁇ D , DBM, L, ⁇ ′ D , DBM′, V′.
  • inter refers to the residues of ⁇ D and ⁇ ′ D towards the interface between the domains
  • intra refers to the residues of ⁇ D and ⁇ ′ D towards the inside of each domain
  • ⁇ A and ⁇ B refer to the ⁇ D of the N-terminal domain
  • ⁇ ′A and ⁇ ′B refer to the ⁇ ′ D of the C-terminal domain.
  • DBM column, the letter (N) and (C), respectively, indicate the origin from the N-terminal domain and the C-terminal domain.
  • the loop can be completely or partially replaced by a convenient linker.
  • a convenient linker is preferably flexible.
  • Said flexible linker essentially comprises glycine, serine and threonine residues.
  • Short flexible linker can also be introduced between the loop and the domains.
  • the loop can also be replaced by a loop from any other di-dodecapeptide meganuclease, preferably the I-Dmo I loop.
  • such hybrid meganuclease comprising a first domain from the N-terminal domain of a di-dodecapeptide meganuclease (A) and a second domain from the N-terminal domain of another di-dodecapeptide meganuclease (B) can further comprise, at its N and/or C-terminal end, a loop or linker and any additional domain.
  • said additional domain is a DNA binding domain, a transcription activator or repressor domain, a nuclear localization signal, or a DNA cleavage domain.
  • the endonuclease activity of such hybrid can be abolished.
  • a hybrid meganuclease comprising or consisting of a first domain derived from the N-terminal domain of a di-dodecapeptide meganuclease (A) and a second domain derived from the N-terminal domain of the same di-dodecapeptide meganuclease (A), said first and second domains being bound by a convenient linker, is also contemplated in the present invention.
  • the same rules of design are applied to this kind of meganuclease.
  • a third embodiment concerns a hybrid meganuclease comprising or consisting of a first domain from the N-terminal domain of a di-dodecapeptide meganuclease (A) and a second domain from another mono-dodecapeptide meganuclease (B), said first and second domains being bound by a convenient linker.
  • the swapping point is positioned at any convenient place. It is preferably positioned at the end of the loop (LA) preceding the second dodecapeptide motif ( ⁇ ′ D ) of the meganuclease (A) or in the helix ⁇ D . In one preferred embodiment, the swapping point is positioned within the helix ⁇ ′ D .
  • the swapping point is positioned in the helix ⁇ ′ D before the dodecapeptide motif itself.
  • the resulting hybrid meganuclease comprises, from the N-terminal end to C-terminal end, the N-terminal domain of the meganuclease A and the domain of the meganuclease B.
  • Such hybrid meganuclease schematically comprises: Type V optional ⁇ D DBM L ⁇ ′ D DBM′ V′ optional 1 A ⁇ A A(N) A ⁇ ′A B B 2 A ⁇ A A(N) A ⁇ ′A/ ⁇ B B B 3 A ⁇ A A(N) A ⁇ B B B A and B indicating the meganuclease at the origin of the segment V, ⁇ D , DBM, L, ⁇ ′ D , DBM′, V′.
  • A/B indicates that the swapping point is into the segment, the origin of the first part of the element is A and that of the second part is B.
  • ⁇ A and ⁇ B refer to the ⁇ D of the N-terminal domain and ⁇ ′A and ⁇ ′B refer to the ⁇ ′ D of the C-terminal domain.
  • DBM DBM
  • N and C respectively, indicate the origin from the N-terminal domain and the C-terminal domain.
  • the invention concerns more particularly a hybrid meganuclease I-Dmo I/I-Cre I comprising or consisting of a first domain from the N-terminal domain of I-Dmo I meganuclease and a second domain from I-Cre I meganuclease, said first and second domains being bound by a convenient linker.
  • said convenient linker is the I-Dmo I meganuclease loop.
  • the swapping point is positioned in the helix ⁇ ′ D before the dodecapeptide motif itself.
  • the invention concerns the hybrid meganucleases I-Dmo I/I-Cre I disclosed in example 1 and in FIG. 6 or a variant thereof.
  • the swapping point is replaced by a swapping domain.
  • the helices ⁇ D and ⁇ ′ D of the hybrid meganuclease can be a mixture of the two initial meganucleases.
  • the amino acid residues from the helices ⁇ D and ⁇ ′ D which are directed towards the helix interface are those of one meganuclease for both helices (those of ⁇ D and ⁇ ′ D from the meganuclease A, or those of ⁇ D from the meganuclease B).
  • the residues at the interface could be derived from another pair of dodecapeptide helices from a mono- or di-dodecapeptide meganuclease X.
  • the amino acid residues from the helices ⁇ D and ⁇ ′ D which are directed towards the inside of the domain are those corresponding to the residues found at that position in that domain of the meganuclease it comes from (those of ⁇ D from the meganuclease A and those of ⁇ D from the meganuclease B).
  • Such hybrid meganuclease schematically comprises: V op- ⁇ D ⁇ ′ D V′ Type tional intra inter DBM L inter intra DBM′ optional 1 A ⁇ A ⁇ A A(N) A ⁇ ′A ⁇ B B B 2 A ⁇ A ⁇ B A(N) A ⁇ B ⁇ B B B 3 A ⁇ A ⁇ X A(N) A ⁇ ′X ⁇ B B B 4 A ⁇ A ⁇ X A(N) A ⁇ X ⁇ B B B A, B, and X indicating the meganuclease at the origin of the segment V, ⁇ D , DBM, L, ⁇ ′ D , DBM′, V′.
  • A/B indicates that the swapping point is into the segment, the origin of the first part of the element is A and that of the second part is B.
  • “inter” refers to the residues of ⁇ D and ⁇ ′ D towards the interface between the domains, and “intra” refers to the residues of ⁇ D and ⁇ ′ D towards the inside of each domain.
  • ⁇ A and ⁇ B refer to the ⁇ D of the N-terminal domain and ⁇ ′A and ⁇ ′B refer to the ⁇ ′ D of the C-terminal domain.
  • DBM column, the letter (N) and (C), respectively, indicate the origin from the N-terminal domain and the C-terminal domain.
  • the loop can be completely or partially replaced by a convenient linker.
  • a convenient linker is preferably flexible.
  • Said flexible linker preferably comprises glycine, serine and threonine residues.
  • Short flexible linker can also be introduced between the loop and the domains.
  • the loop can also be replaced by a loop from any other di-dodecapeptide meganuclease, preferably the I-Dmo I loop.
  • such hybrid meganuclease comprising a first domain from the N-terminal domain of a di-dodecapeptide meganuclease (A) and a second domain from the domain of another mono-dodecapeptide meganuclease (B) can further comprise, at its N-terminal and/or C-terminal end, a loop or linker and any additional domain.
  • said additional domain is a DNA binding domain, a transcription activator or repressor domain, a nuclear localization signal or a DNA cleavage domain.
  • the endonuclease activity of such hybrid can be abolished.
  • a forth preferred embodiment concerns a hybrid meganuclease comprising or consisting of a first domain derived from the C-terminal domain of a di-dodecapeptide meganuclease (A) and a second domain derived from the C-terminal domain of another di-dodecapeptide meganuclease (B), said first and second domains being bound by a convenient linker.
  • the swapping point is positioned at any convenient place. This swapping point can be positioned from the last helix of the DNA binding moiety DBM to the beginning of the loop (LB) preceding the helix ⁇ ′ D . It is preferably positioned at the beginning of the loop (LB) preceding the helix ⁇ ′ D .
  • the resulting hybrid meganuclease comprises the C-terminal domain of the meganucleases A and B.
  • the resulting hybrid meganuclease does not comprise the DBM of the N-terminal domain of the meganuclease A, more preferably its N-terminal domain.
  • Such hybrid meganuclease schematically comprises: V, Type optional ⁇ D DBM L ⁇ ′ D DBM′ V′ optional 1 A ⁇ ′A A(C) B ⁇ ′B B(C) B 2 A ⁇ ′A A(C)/B(N) B ⁇ ′B B(C) B A and B indicating the meganuclease at the origin of the segment V, ⁇ D , DBM, L, ⁇ ′ D , DBM′, V′.
  • A/B indicates that the swapping point is into the segment, the origin of the first part of the element is A and that of the second part is B.
  • ⁇ A and ⁇ B refer to the ⁇ D of the N-terminal domain and ⁇ ′A and ⁇ ′B refer to the ⁇ ′ D of the C-terminal domain.
  • DBM DBM
  • N and C respectively, indicate the origin from the N-terminal domain and the C-terminal domain.
  • the swapping point is replaced by a “swapping domain”.
  • the helices ⁇ D and ⁇ ′ D of the hybrid meganuclease can be a mixture of the two initial meganucleases.
  • the amino acid residues from the helices ⁇ D and ⁇ ′ D which are directed towards the helices interface are those of one meganuclease for both helices ⁇ D and ⁇ ′ D (those of ⁇ D and ⁇ ′ D from the meganuclease A or those of ⁇ D and ⁇ ′ D from the meganuclease B).
  • the residues at the interface could be derived from another pair of dodecapeptide helices from a mono- or di-dodecapeptide meganuclease X.
  • the amino acid residues from the helices ⁇ D and ⁇ ′ D which are directed towards the inside of the domain are those corresponding to the residues found at that position in that domain of the meganuclease it comes from (those of ⁇ ′ D from the meganuclease A and those of ⁇ ′ D from the meganuclease B).
  • Such hybrid meganuclease schematically comprises: V′ V op- ⁇ D ⁇ ′ D op- Type tional intra inter DBM′ L inter intra DBM′ tional 1 A ⁇ ′A ⁇ A A(C) B ⁇ ′A ⁇ ′B B(C) B 2 A ⁇ ′A ⁇ B A(C) B ⁇ ′B ⁇ ′B B(C) B 3 A ⁇ ′A ⁇ X A(C) B ⁇ ′X ⁇ ′B B(C) B 4 A ⁇ ′A ⁇ X A(C) B ⁇ X ⁇ ′B B(C) B 5 A ⁇ ′A ⁇ A A(C)/ B ⁇ ′A ⁇ ′B B(C) B B(N) 6 A ⁇ ′A ⁇ B A(C)/ B ⁇ ′B ⁇ ′B B(C) B B(N) 7 A ⁇ ′A ⁇ X A(C)/ B ⁇ ′X ⁇ ′B B(C) B B(N) 8 A
  • A/B indicates that the swapping point is into the segment, the origin of the first part of the element is A and that of the second part is B.
  • “inter” refers to the residues of ⁇ D and ⁇ ′ D towards the interface between the domains, and “intra” refers to the residues of ⁇ D and ⁇ ′ D towards the inside of each domain.
  • ⁇ A and ⁇ B refer to the ⁇ D of the N-terminal domain and ⁇ ′A and ⁇ ′B refer to the ⁇ ′ D of the C-terminal domain.
  • DBM column, the letter (N) and (C), respectively, indicate the origin from the N-terminal domain and the C-terminal domain.
  • the loop can be completely or partially replaced by a convenient linker.
  • a convenient linker is preferably flexible.
  • Said flexible linker preferably comprises glycine, serine and threonine residues.
  • Short flexible linker can also be introduced between the loop and the domains.
  • the loop can also be replaced by a loop from any other di-dodecapeptide meganuclease, preferably the I-Dmo I loop.
  • such hybrid meganuclease comprising a first domain from the C-terminal domain of a di-dodecapeptide meganuclease (A) and a second domain from the C-terminal domain of another di-dodecapeptide meganuclease (B) can further comprise, at its N-terminal and/or C-terminal end, a loop or linker and any additional domain.
  • said additional domain is a DNA binding domain, a transcription activator or repressor domain, a nuclear localization signal or a DNA cleavage domain.
  • the endonuclease activity of such hybrid can be abolished.
  • a hybrid meganuclease comprising or consisting of a first domain derived from the C-terminal domain of a di-dodecapeptide meganuclease (A) and a second domain derived from the C-terminal domain of the same di-dodecapeptide meganuclease (A), said first and second domains being bound by a convenient linker, is also contemplated in the present invention.
  • the same rules of design are applied to this kind of meganuclease.
  • a fifth embodiment concerns a hybrid meganuclease comprising or consisting of a first domain from the domain of a mono-dodecapeptide meganuclease (A) and a second domain from the C-terminal domain of another di-dodecapeptide meganuclease (B), said first and second domains being bound by a convenient linker.
  • the swapping point can be positioned from the last helix of the DNA binding moiety DBM to the beginning of the loop (LB) preceding the helix ⁇ ′ D . It is preferably positioned at the beginning of the loop (LB) preceding the helix ( ⁇ ′ D ).
  • the resulting hybrid meganuclease comprises, from the N-terminal end to C-terminal end, the domain of the meganuclease A and the C-terminal domain of the meganuclease B.
  • Such hybrid meganuclease schematically comprises: Type V optional ⁇ D DBM L ⁇ ′ D DBM′ V′ optional 1 A ⁇ A A B ⁇ ′B B(C) B 2 A ⁇ A A/B(N) B ⁇ ′B B(C) B A and B indicating the meganuclease at the origin of the segment V, ⁇ D , DBM, L, ⁇ ′ D , DBM′, V′.
  • A/B indicates that the swapping point is into the segment, the origin of the first part of the element is A and that of the second part is B.
  • ⁇ A and ⁇ B refer to the ⁇ D of the N-terminal domain and ⁇ ′A and ⁇ ′B refer to the ⁇ ′ D of the C-terminal domain.
  • DBM bitmap
  • the swapping point is replaced by a “swapping domain”.
  • the helices ⁇ D and ⁇ ′ D of the hybrid meganuclease can be a mixture of the two initial meganucleases.
  • the amino acid residues from the helices ⁇ D and ⁇ ′ D which are directed towards the helices interface are those of one meganuclease for both helices ⁇ D and ⁇ ′ D (those of ⁇ D from the meganuclease A or those of ⁇ D and ⁇ ′ D from the meganuclease B).
  • the residues at the interface could be derived from another pair of dodecapeptide helices from a mono- or di-dodecapeptide meganuclease X.
  • the amino acid residues from the helices ⁇ D and ⁇ ′ D which are directed towards the inside of the domain are those corresponding to the residues found at that position in that domain of the meganuclease it comes from (those of ⁇ D from the meganuclease A and those of ⁇ ′ D from the maganuclease B).
  • Such hybrid meganuclease schematically comprises: V′ V op- ⁇ D ⁇ ′ D op- Type tional intra inter DBM L inter intra DBM′ tional 1 A ⁇ A ⁇ A A B ⁇ A ⁇ ′B B(C) B 2 A ⁇ A ⁇ B A B ⁇ ′B ⁇ ′B B(C) B 3 A ⁇ A ⁇ X A B ⁇ ′X ⁇ ′B B(C) B 4 A ⁇ A ⁇ X A B ⁇ X ⁇ ′B B(C) B 5 A ⁇ A ⁇ A A/B(N) B ⁇ A ⁇ ′B B(C) B 6 A ⁇ A ⁇ B A/B(N) B ⁇ ′B ⁇ ′B B(C) B 7 A ⁇ A ⁇ X A/B(N) B ⁇ ′X ⁇ ′B B(C) B 8 A ⁇ A ⁇ X A/B(N) B ⁇ X ⁇ ′B B(C) B A, B, and
  • A/B indicates that the swapping point is into the segment, the origin of the first part of the element is A and that of the second part is B.
  • “inter” refers to the residues of ⁇ D and ⁇ ′ D towards the interface between the domains, and “intra” refers to the residues of ⁇ D and ⁇ ′ D towards the inside of each domain.
  • ⁇ A and ⁇ B refer to the ⁇ D of the N-terminal domain and ⁇ ′A and ⁇ ′B refer to the ⁇ ′ D of the C-terminal domain.
  • DBM column, the letter (N) and (C), respectively, indicate the origin from the N-terminal domain and the C-terminal domain.
  • the loop can be completely or partially replaced by a convenient linker.
  • a convenient linker is preferably flexible.
  • Said flexible linker essentially comprises glycine, serine and threonine residues.
  • Short flexible linker can also be introduced between the loop and the domains.
  • the loop can also be replaced by a loop from any other di-dodecapeptide meganuclease, preferably the I-Dmo I loop.
  • such hybrid meganuclease comprising a first domain from the domain of a mono-dodecapeptide meganuclease (A) and a second domain from the C-terminal domain of another di-dodecapeptide meganuclease (B) can further comprise, at its N-terminal and/or C-terminal end, a loop or linker and any additional domain.
  • said additional domain is a DNA binding domain, a transcription activator or repressor domain, a nuclear localization signal or a DNA cleavage domain.
  • the endonuclease activity of such hybrid can be abolished.
  • a sixth embodiment concerns a hybrid meganuclease comprising or consisting of a first domain derived from the C-terminal domain of a di-dodecapeptide meganuclease (A) and a second domain derived from the N-terminal domain of another di-dodecapeptide meganuclease (B), said first and second domains being bound by a convenient linker.
  • the first and the second domains are linked by either a convenient linker or a connecting loop from any di-dodecapeptide meganuclease Y, for example the loop of I-Dmo I meganuclease.
  • a convenient linker is preferably flexible.
  • Said flexible linker essentially comprises glycine, serine and threonine residues. Short flexible linkers can also be introduced between the loop and the domains.
  • the linker is preferably attached at one end to the helix following the 4-stranded 1-sheet of the DBM of the C-terminal domain of the meganuclease A and at the other end at the helix cc D of the N-terminal domain of the meganuclease B.
  • the resulting hybrid meganuclease comprises, from the N-terminal end to C-terminal end, the C-terminal domain of the meganuclease A, a linker or a connecting loop and the N-terminal domain of the meganuclease B.
  • the resulting hybrid meganuclease does not comprise the DBM of the N-terminal domain of the meganuclease A, more preferably its N-terminal domain.
  • the resulting hybrid meganuclease does not comprise the DBM of the C-terminal domain of the meganuclease B, more preferably its C-terminal domain.
  • Such hybrid meganuclease schematically comprises: V, optional ⁇ D DBM L ⁇ ′ D DBM′ V′, optional A ⁇ ′A A(C) Y ⁇ B B(N) B A, B and Y indicating the meganuclease at the origin of the segment V, ⁇ D , DBM, L, ⁇ ′ D , DBM′, V′.
  • ⁇ A and ⁇ B refer to the ⁇ D of the N-terminal domain and ⁇ ′A and ⁇ ′B refer to the ⁇ ′ D of the C-terminal domain.
  • DBM the letter (N) and (C), respectively, indicate the origin from the N-terminal domain and the C-terminal domain.
  • the helices ⁇ D and ⁇ ′ D of the hybrid meganuclease can be a mixture of the two initial meganucleases.
  • the amino acid residues from the helices ⁇ D and ⁇ ′ D which are directed towards the helix interface are those of one meganuclease for both helices ⁇ D and ⁇ ′ D (those of ⁇ D and ⁇ ′ D from the meganuclease A or B).).
  • the residues at the interface could be derived from another pair of dodecapeptide helices from a mono- or di-dodecapeptide meganuclease X.
  • amino acid residues from the helices ⁇ D and ⁇ ′ D which are directed towards the inside of the domain are those corresponding to the residues found at that position in that domain of the meganuclease it comes from (those of ⁇ ′ D from the meganuclease A and those of ⁇ D from the meganuclease B).
  • Such hybrid meganuclease schematically comprises: V, op- ⁇ D ⁇ ′ D V′, Type tional intra inter DBM L inter intra DBM′ optional 1 A ⁇ ′A ⁇ A A(C) Y ⁇ ′A ⁇ B B(N) B 2 A ⁇ ′A ⁇ B A(C) Y ⁇ ′B ⁇ B B(N) B 3 A ⁇ ′A ⁇ X A(C) Y ⁇ ′X ⁇ B B(N) B 4 A ⁇ ′A ⁇ X A(C) Y ⁇ X ⁇ B B(N) B A, B, X and Y indicating the meganuclease at the origin of the segment V, ⁇ D , DBM, L, ⁇ ′ D , DBM′, V′.
  • inter refers to the residues of ⁇ D and ⁇ ′ D towards the interface between the domains
  • intra refers to the residues of ⁇ D and ⁇ ′ D towards the inside of each domain
  • ⁇ A and ⁇ B refer to the ⁇ D of the N-terminal domain
  • ⁇ ′A and ⁇ ′B refer to the ⁇ ′ D of the C-terminal domain.
  • DBM column, the letter (N) and (C), respectively, indicate the origin from the N-terminal domain and the C-terminal domain.
  • amino acid modifications can be further introduced in order to avoid the steric hindrance between amino acid side chains and/or to increase the stability.
  • some amino acid modifications can be further introduced in order to enhance the production and/or the solubility and to decrease the toxicity (Turmel et al, 1997, Nucleic Acid Research, 25, 2610-2619).
  • such hybrid meganuclease comprising a first domain from the C-terminal domain of a di-dodecapeptide meganuclease (A) and a second domain from the N-terminal domain of another di-dodecapeptide meganuclease (B) can further comprise, at its N-terminal and/or C-terminal end, a loop or linker and any additional domain.
  • said additional domain is a DNA binding domain, a transcription activator or repressor domain, a nuclear localization signal or a DNA cleavage domain.
  • the endonuclease activity of such hybrid can be abolished.
  • a hybrid meganuclease comprising or consisting of a first domain derived from the C-terminal domain of a di-dodecapeptide meganuclease (A) and a second domain derived from the N-terminal domain of the same di-dodecapeptide meganuclease (A), said first and second domains being bound by a convenient linker, is also contemplated in the present invention.
  • the same rules of design are applied to this kind of meganuclease.
  • a seventh embodiment concerns a hybrid meganuclease comprising or consisting of a first domain derived from the domain of a mono-dodecapeptide meganuclease (A) and a second domain derived from the N-terminal domain of another di-dodecapeptide meganuclease (B), said first and second domains being bound by a convenient linker.
  • the first and the second domains are linked by either a convenient linker or a connecting loop from any di-dodecapeptide meganuclease Y, for example the loop of I-Dmo I meganuclease.
  • a convenient linker is preferably flexible. Said flexible linker essentially comprises glycine, serine and threonine residues.
  • Short flexible linker can also be introduced between the loop and the domains.
  • the linker is preferably attached at one end to the helix following the 4-stranded O-sheet of the DBM of the domain of the meganuclease A and at the other end at the helix ⁇ D of the N-terminal domain of the meganuclease B.
  • the resulting hybrid meganuclease comprises, from the N-terminal end to C-terminal end, the domain of the meganuclease A, a linker or a connecting loop and the N-terminal domain of the meganuclease B.
  • the resulting hybrid meganuclease does not comprise the DBM of the C-terminal domain of the meganuclease B, more preferably its C-terminal domain.
  • Such hybrid meganuclease schematically comprises: V, optional ⁇ D DBM L ⁇ ′ D DBM′ V′, optional A ⁇ A A Y ⁇ B B(N) B A, B and Y indicating the meganuclease at the origin of the segment V, ⁇ D , DBM, L, ⁇ ′ D , DBM′, V′.
  • ⁇ A and ⁇ B refer to the ⁇ D of the N-terminal domain and ⁇ ′A and ⁇ ′B refer to the ⁇ ′ D of the C-terminal domain.
  • DBM the letter (N) and (C), respectively, indicate the origin from the N-terminal domain and the C-terminal domain.
  • the helices ⁇ D and ⁇ ′ D of the hybrid meganuclease can be a mixture of the two initial meganucleases.
  • the amino acid residues from the helices ⁇ D and ⁇ ′ D which are directed towards the helix interface are those of one meganuclease for both helices (those of ⁇ D from the meganuclease A, or those of ⁇ D and ⁇ ′ D from the meganuclease B).
  • the residues at the interface could be derived from another pair of dodecapeptide helices from a mono- or di-dodecapeptide meganuclease X.
  • amino acid residues from the helices ⁇ D and ⁇ ′ D which are directed towards the inside of the domain are those corresponding to the residues found at that position in that domain of the meganuclease it comes from (those of ⁇ D from the meganuclease A and those of ⁇ D from the meganuclease B).
  • Such hybrid meganuclease schematically comprises: V, op- ⁇ D ⁇ ′ D V′, Type tional intra inter DBM L inter intra DBM′ optional 1 A ⁇ A ⁇ A A Y ⁇ A ⁇ B B(N) B 2 A ⁇ A ⁇ B A Y ⁇ ′B ⁇ B B(N) B 3 A ⁇ A ⁇ X A Y ⁇ ′X ⁇ B B(N) B 4 A ⁇ A ⁇ X A Y ⁇ X ⁇ B B(N) B A, B, X and Y indicating the meganuclease at the origin of the segment V, ⁇ D , DBM, L, ⁇ ′ D , DBM′, V′.
  • inter refers to the residues of ⁇ D and ⁇ ′ D towards the interface between the domains
  • intra refers to the residues of ⁇ D and ⁇ ′ D towards the inside of each domain
  • ⁇ A and ⁇ B refer to the ⁇ D of the N-terminal domain
  • ⁇ ′A and ⁇ ′B refer to the ⁇ ′ D of the C-terminal domain.
  • DBM column, the letter (N) and (C), respectively, indicate the origin from the N-terminal domain and the C-terminal domain.
  • amino acid modifications can be further introduced in order to avoid the steric hindrance between amino acid side chains and/or to increase the stability.
  • some amino acid modifications can be further introduced in order to enhance the production and/or the solubility and to decrease the toxicity (Turmel et al, 1997, Nucleic Acid Research, 25, 2610-2619).
  • such hybrid meganuclease comprising a first domain from the domain of a mono-dodecapeptide meganuclease (A) and a second domain from the N-terminal domain of another di-dodecapeptide meganuclease (B) can further comprise, at its N-terminal and/or C-terminal end, a loop or linker and any additional domain.
  • said additional domain is a DNA binding domain, a transcription activator or repressor domain, a nuclear localization signal or a DNA cleavage domain.
  • the endonuclease activity of such hybrid can be abolished.
  • a eighth embodiment concerns a hybrid meganuclease comprising or consisting of a first domain derived from the C-terminal domain of a di-dodecapeptide meganuclease (A) and a second domain derived from the domain of another mono-dodecapeptide meganuclease (B), said first and second domains being bound by a convenient linker.
  • the first and the second domains are linked by either a convenient linker or a connecting loop from any di-dodecapeptide meganuclease Y, for example the loop of I-Dmo I meganuclease.
  • a convenient linker is preferably flexible. Said flexible linker essentially comprises glycine, serine and threonine residues.
  • Short flexible linker can also be introduced between the loop and the domains.
  • the linker is preferably attached at one end to the helix following the 4-stranded ⁇ -sheet of the DBM of the C-terminal domain of the meganuclease A and at the other end at the helix ⁇ D of the domain of the meganuclease B.
  • the resulting hybrid meganuclease comprises, from the N-terminal end to C-terminal end, the C-terminal domain of the meganuclease A, a linker or a connecting loop and the domain of the meganuclease B.
  • the resulting hybrid meganuclease does not comprise the DBM of the N-terminal domain of the meganuclease A, more preferably its N-terminal domain.
  • Such hybrid meganuclease schematically comprises: V, optional ⁇ D DBM L ⁇ ′ D DBM′ V′, optional A ⁇ ′A A(C) Y ⁇ B B B A, B, and Y indicating the meganuclease at the origin of the segment V, ⁇ D , DBM, L, ⁇ ′ D , DBM′, V′.
  • ⁇ A and ⁇ B refer to the ⁇ D of the N-terminal domain
  • ⁇ ′A and ⁇ ′B refer to the ⁇ ′ D of the C-terminal domain.
  • DBM the letter (N) and (C), respectively, indicate the origin from the N-terminal domain and the C-terminal domain.
  • the helices ⁇ D and ⁇ ′ D of the hybrid meganuclease can be a mixture of the two initial meganucleases.
  • the amino acid residues from the helices ⁇ D and ⁇ ′ D which are directed towards the helix interface are those of one meganuclease for both helices (those of ⁇ D and ⁇ ′ D from the meganuclease A, or those of ⁇ D from the meganuclease B).
  • the residues at the interface could be derived from another pair of dodecapeptide helices from a mono- or di-dodecapeptide meganuclease X.
  • amino acid residues from the helices ⁇ D and ⁇ ′ D which are directed towards the inside of the domain are those corresponding to the residues found at that position in that domain of the meganuclease it comes from (those of ⁇ ′ D from the meganuclease A and those of ⁇ D from the meganuclease B).
  • Such hybrid meganuclease schematically comprises: V, op- ⁇ D ⁇ ′ D V′, Type tional intra inter DBM L inter intra DBM′ optional 1 A ⁇ ′A ⁇ A A(C) Y ⁇ ′A ⁇ B B B 2 A ⁇ ′A ⁇ B A(C) Y ⁇ B ⁇ B B B 3 A ⁇ ′A ⁇ X A(C) Y ⁇ X ⁇ B B B 4 A ⁇ ′A ⁇ X A(C) Y ⁇ ′X ⁇ B B B A, B, X and Y indicating the meganuclease at the origin of the segment V, ⁇ D , DBM, L, ⁇ ′ D , DBM′, V′.
  • inter refers to the residues of ⁇ D and ⁇ ′ D towards the interface between the domains
  • intra refers to the residues of ⁇ D and ⁇ ′ D towards the inside of each domain
  • ⁇ A and ⁇ B refer to the ⁇ D of the N-terminal domain
  • ⁇ ′A and ⁇ ′B refer to the ⁇ ′ D of the C-terminal domain.
  • DBM column, the letter (N) and (C), respectively, indicate the origin from the N-terminal domain and the C-terminal domain.
  • amino acid modifications can be further introduced in order to avoid the steric hindrance between amino acid side chains and/or to increase the stability.
  • some amino acid modifications can be further introduced in order to enhance the production and/or the solubility and to decrease the toxicity (Turmel et al, 1997, Nucleic Acid Research, 25, 2610-2619).
  • such hybrid meganuclease comprising a first domain from the C-terminal domain of a di-dodecapeptide meganuclease (A) and a second domain from the domain of another mono-dodecapeptide meganuclease (B) can further comprise, at its N-terminal and/or C-terminal end, a loop or linker and any additional domain.
  • said additional domain is a DNA binding domain, a transcription activator or repressor domain, a nuclear localization signal or a DNA cleavage domain.
  • the endonuclease activity of such hybrid can be abolished.
  • a ninth embodiment concerns a hybrid meganuclease comprising or consisting of a first domain derived from the domain of a mono-dodecapeptide meganuclease (A) and a second domain derived from the domain of the same or another mono-dodecapeptide meganuclease (B), said first and second domains being bound by a convenient linker.
  • the first and the second domains are linked by either a convenient linker or a connecting loop from any di-dodecapeptide meganuclease Y, for example the loop of I-Dmo I meganuclease.
  • a convenient linker is preferably flexible. Said flexible linker essentially comprises glycine, serine and threonine residues.
  • Short flexible linker can also be introduced between the loop and the domains.
  • the linker is preferably attached at one end to the helix following the 4-stranded O-sheet of the DBM of the domain of the meganuclease A and at the other end at the helix ⁇ D of the domain of the meganuclease B.
  • the resulting hybrid meganuclease comprises, from the N-terminal end to C-terminal end, the domain of the meganuclease A deleted from the variable sequence VA located downstream of the DBM of B, a linker or a connecting loop and the domain of the meganuclease B.
  • Such hybrid meganuclease schematically comprises: V, optional ⁇ D DBM L ⁇ ′ D DBM′ V′, optional A ⁇ A A Y ⁇ B B B A, B and Y indicating the meganuclease at the origin of the segment V, ⁇ D , DBM, L, ⁇ ′ D , DBM′, V′.
  • ⁇ A and ⁇ B refer to the ⁇ D of the N-terminal domain
  • ⁇ ′A and ⁇ ′B refer to the ⁇ ′ D of the C-terminal domain.
  • DBM the letter (N) and (C), respectively, indicate the origin from the N-terminal domain and the C-terminal domain.
  • the helices ⁇ D and ⁇ ′ D of the hybrid meganuclease can be a mixture of the two initial meganucleases.
  • the amino acid residues from the helices ⁇ D and ⁇ ′ D which are directed towards the helix interface are those of one meganuclease for both helices (those of ⁇ D from the meganuclease A or B).
  • the residues at the interface could be derived from another pair of dodecapeptide helices from a mono- or di-dodecapeptide meganuclease X.
  • amino acid residues from the helices ⁇ D and ⁇ ′ D which are directed towards the inside of the domain are those corresponding to the residues found at that position in that domain of the meganuclease it comes from (those of ⁇ D from the meganuclease A and B).
  • Such hybrid meganuclease schematically comprises: V, op- ⁇ D ⁇ ′ D V′, Type tional intra inter DBM L inter intra DBM′ optional 1 A ⁇ A ⁇ A A Y ⁇ A ⁇ B B B 2 A ⁇ A ⁇ B A Y ⁇ B ⁇ B B B 3 A ⁇ A ⁇ X A Y ⁇ ′X ⁇ B B B 4 A ⁇ A ⁇ X A Y ⁇ X ⁇ B B B A, B, Y and X indicating the meganuclease at the origin of the segment V, ⁇ D , DBM, L, ⁇ ′ D , DBM′, V′.
  • inter refers to the residues of ⁇ D and ⁇ ′ D towards the interface between the domains
  • intra refers to the residues of ⁇ D and ⁇ ′ D towards the inside of each domain
  • ⁇ A and ⁇ B refer to the ⁇ D of the N-terminal domain
  • ⁇ ′A and ⁇ ′B refer to the ⁇ ′ D of the C-terminal domain.
  • DBM column, the letter (N) and (C), respectively, indicate the origin from the N-terminal domain and the C-terminal domain.
  • amino acid modifications can be further introduced in order to avoid the steric hindrance between amino acid side chains and/or to increase the stability.
  • some amino acid modifications can be further introduced in order to enhance the production and/or the solubility and to decrease the toxicity (Turmel et al, 1997, Nucleic cod Research, 25, 2610-2619).
  • such hybrid meganuclease comprising a first domain from the domain of a mono-dodecapeptide meganuclease (A) and a second domain from the domain of another mono-dodecapeptide meganuclease (B) can further comprise, at its N-terminal and/or C-terminal end, a loop or linker and any additional domain.
  • said additional domain is a DNA binding domain, a transcription activator or repressor domain, a nuclear localization domain or a DNA cleavage domain.
  • the endonuclease activity of such hybrid can be abolished.
  • hybrid meganuclease more particularly a hybrid meganuclease comprising a first domain derived from the N-terminal domain of a di-dodecapeptide meganuclease (A) and a second domain derived from the C-terminal domain of another di-dodecapeptide meganuclease (B), is disclosed in example 1 for the I-Dmo I/I-Cre I hybrid meganuclease.
  • An example of one way for introducing said linker between two domains is disclosed in example 2 for the single chain I-Cre I meganuclease.
  • a flexible linker could be a sequence comprising a number of glycine, serine and threonine amino acids.
  • a disadvantage, not present in our method, could be the need, in this case, to determine and eventually optimize for each domain combination the precise linker sequence and length, together with the connections to the protein domains.
  • the invention also contemplates the use of such hybrid meganuclease essentially as recognition domain.
  • the endonculease catalytic activity of the hybrid meganuclease can be abolished by some mutation, for example the acidic residues D/E which are necessary for the catalytic activity.
  • the invention concerns a chimeric protein comprising one domain derived from a dodecapeptide meganuclease, a linker and an helix comprising the dodecapeptide motif
  • said linker is a loop from a di-dodecapeptide meganuclease.
  • said chimeric protein further comprises an additional domain.
  • Said additional domain is preferably a DNA binding domain, a transcription activator or repressor domain, a nuclear localization signal, or a DNA cleavage domain
  • a Single-chain meganuclease derived from “mono-dodecapeptide” meganucleases are active as homodimer. Each monomer mainly dimerizes through their dodecapeptide motifs.
  • This single-chain meganuclease covalently binds two monomers of a “mono-dodecapeptide” meganuclease modified such as to introduce a covalent link between the two sub-units of this enzyme.
  • the covalent link is introduced by creating a peptide bond between the two monomers.
  • others convenient covalent link are also contemplated by the present invention.
  • the invention concerns a single-chain meganuclease comprising a first and a second domain in the orientation N-terminal toward C-terminal, wherein said first and second domains are derived from the same mono-dodecapeptide meganuclease and wherein said single-chain meganuclease is capable of causing DNA cleavage.
  • the single-chain meganuclease can comprise two sub-units from the same meganuclease such as single-chain I-Cre and single-chain I-Ceu I.
  • the single-chain I-Ceu II is also contemplated by the invention. See example 2 for the single-chain I-Cre I.
  • the invention concerns a single chain meganuclease of 1-Cre comprising the sequence of SEQ ID No. 6.
  • a single-chain meganuclease has multiple advantages. For example, a single-chain meganuclease is easier to manipulate. The single-chain meganuclease is thermodynamically favored, for example for the recognition of the target sequence, compared to a dimer formation. The single-chain meganuclease allows the control of the oligomerisation. Same principles of hybrid meganucleases apply to the single chain meganuclease.
  • hybrid meganuclease comprising a first domain derived from the domain of a mono-dodecapeptide meganuclease (A) and a second domain derived from the domain of the same or another mono-dodecapeptide meganuclease (E).
  • the invention also relates to variants of the hybrid or single chain meganuclease according to the present invention.
  • the variants of hybrid or single chain meganuclease comprise a core of the meganuclease consisting of the two domains and the linker having at least 70% of identity with the initial hybrid or single chain meganuclease, more preferably at least 80, 90, 95 or 99% of identity.
  • the variant may be 1) one in which one or more of the amino acid residues are substituted with a conserved or non-conserved amino acid residue and such substituted amino acid residue may or may not be one encoded by the genetic code, or 2) one in which one or more of the amino acid residues includes a substituent group, or 3) one in which the hybrid or single chain meganuclease is fused with another compound, such as a compound to increase the half-life of the polypeptide (for example, polyethylene glycol), or 4) one in which the additional amino acids are fused to the hybrid meganuclease, such as a leader or secretory sequence or a sequence which is employed for purification of the hybrid meganuclease.
  • amino acid substitution in the amino acid sequence of a hybrid or single chain meganuclease according to the invention, one or several amino acids can be replaced by “equivalent” amino acids.
  • the expression “equivalent” amino acid is used herein to designate any amino acid that may be substituted for one of the amino acids having similar properties, such that one skilled in the art of peptide chemistry would expect the secondary structure and hydropathic nature of the polypeptide to be substantially unchanged.
  • amino acids represent equivalent changes: (1) Ala, Pro, Gly, Glu, Asp, Gln, Asn, Ser, Thr; (2) Cys, Ser, Tyr, Thr; (3) Val, Ile, Leu, Met, Ala, Phe; (4) Lys, Arg, His; (5) Phe, Tyr, Trp, His.
  • a modifed hyrbid or single chain meganuclease is a peptide molecule which is resistant to proteolysis, a peptide in which the-CONH-peptide bond is modified and replaced by a (CH2NH) reduced bond, a (NHCO) retro inverso bond, a (CH2-O) methylene-oxy bond, a (CH2-S) thiomethylene bond, a (CH2CH2) carba bond, a (CO—CH2) cetomethylene bond, a (CHOH—CH2) hydroxyethylene bond), a (N—N) bound, a E-alcene bond or also a-CH ⁇ CH-bond.
  • the invention also encompasses a hyrbid or single chain meganuclease in which at least one peptide bound has been modified as described above.
  • the present invention concerns any cell or non-human animal comprising a hybrid or single chain meganuclease according to the present invention.
  • the present invention also comprises any pharmaceutical composition comprising a hybrid or single chain meganuclease according to the present invention.
  • the present invention concerns a recombinant polynucleotide encoding a hybrid or single chain meganuclease according to the present invention.
  • the invention concerns a polynucleotide comprising a sequence selected from the group consisting of SEQ ID No. 1, 3 and 5.
  • the present invention concerns:
  • any vector comprising a polynucleotide sequence encoding a hybrid or single chain meganuclease according to the present invention
  • any prokaryotic or eukaryotic cell comprising either a polynucleotide sequence encoding a hybrid or single chain meganuclease according to the present invention or said vector comprising said polynucleotide sequence;
  • any non-human animal comprising a polynucleotide sequence encoding a hybrid or single chain meganuclease according to the present invention, a vector comprising said polynucleotide, or a cell comprising either said polynucleotide or a vector comprising said polynucleotide.
  • the vector comprising a polynucleotide encoding a hybrid or single chain meganuclease contains all or part of the coding sequence for said a hybrid or single chain meganuclease operably linked to one or more expression control sequences whereby the coding sequence is under the control of transcriptional signals to permit production or synthesis of said hybrid or single chain meganuclease. Therefore, said polynucleotide encoding a hybrid or single chain meganuclease is comprised in an expression cassette.
  • the vector comprises a replication origin, a promoter operatively linked to said encoding polynucleotide, a ribosome-binding site, an RNA-splicing site (when genomic DNA is used), a polyadenylation site and a transcription termination site. It also can comprise an enhancer. Selection of the promoter will depend upon the desired route for expressing the hybrid or single chain meganuclease.
  • the invention concerns a method for producing a hybrid or single chain meganuclease comprising introducing an expression vector into a cell compatible with the element of said expression vector.
  • the polynucleotide sequence encoding the hybrid or single chain meganuclease can be prepared by any method known.
  • the polynucleotide sequence encoding the hybrid or single chain meganuclease can be prepared from the polynucleotide sequences encoding the initial meganucleases by usual molecular biology technologies.
  • the polynucleotide sequence encoding the hybrid or single chain meganuclease is preferably generated by well-known back or reverse-translation methods. Number of back-translation softs are available, for example in the GCG sequence analysis package (University of Wisconsin, Madison, Wis.).; in DNA strider, in EMBOSS (European Molecular Biology Open Software Suite: http://www.hgmp.mrc.ac.uk/Software/EMBOSS/Apps/backtranseq.html); etc. . . . ).
  • the obtained polynucleotide sequence can be synthetized through any method well known by the man skilled in the art.
  • hybrid meganucleases recognize and cleave a hybrid site or target comprising the half sites recognized by each domains comprised in the hybrid meganuclease.
  • the recognition sites of the meganucleases are not palyndromic.
  • Site L A the N-terminal and C-terminal domains recognize two different half recognition sites; herein called “Site L A ” and “Site R A ”.
  • the indicated sequences for the initial half sites generally correspond to the sequence of the strand + of the genome. “L” refers to the left part of the site and “R” to the right part. Therefore, the site of the meganuclease A can be described as Site L A -Site R A .
  • RC Site is intended in the present invention the reverse complementary sequence of the half site on the + strand of the genomic target site.
  • the orientation of the parental molecules onto their respective recognition and cleavage site is not always well defined or known.
  • several half-site combinations have to be synthesized and subjected to cleavage.
  • the following target sites will be preferably used;
  • the hybrid site can be easily defined without any combination.
  • the determination of the orientation can be determined by the generation of hybrid meganuclease and the study of their specificity on the several targets of the above mentioned combination. See example 3 (I-Dmo I/I-Cre I) for a way of determination of the respective orientation of the meganuclease and the recognition site.
  • synthetic target site corresponding to the fusion of parental half sites or a combination thereof is synthesized and cloned into a vector or use as such.
  • the invention concerns an isolated or recombinant polynucleotide comprising a hybrid target site according to the present invention.
  • This hybrid target site comprises two half sites from the initial meganucleases, one per meganuclease.
  • the invention also concerns a vector comprising a hybrid target site according to the present invention.
  • the invention further concerns a cell comprising a recombinant polynucleotide or a vector comprising a hybrid target site according to the present invention.
  • the invention further concerns a non-human animal comprising a recombinant polynucleotide or a vector comprising a hybrid target site according to the present invention.
  • the invention further concerns a plant comprising a recombinant polynucleotide or a vector comprising a hybrid target site according to the present invention.
  • Homing intron-encoded meganuclease of the dodecapeptide family recognize and cleave normally a sequence present in a gene without intron, said intron comprising the encoding sequence for the meganuclease.
  • the target sequence for the meganuclease is represented by the junction of upstream and downstream exon, naturally present in the gene without intron.
  • the length of the recognition site should be 30 nucleotides on the left part (upstream exon) and 30 nucleotides on the right side (downstream exon) meaning 60 nucleotides to test the binding and/or the cleavage of the protein.
  • the recognition sequence should be centered around the position of the intron insertion point in the gene without intron.
  • the recognition site In the absence of data on the recognition site, one difference with the determination of the site of intron-encoded meganucleases, could be the presence of a cystein codon (observed in a large number of cases) in the middle of the recognition sequence (TGT or TGC).
  • the canonical target sequence should be represented by the junction between the two half-site of each original meganuclease.
  • the recognition and cleavage of a specific DNA sequence by the hybrid and/or single chain meganucleases according to the present invention can be assayed by any method known by the man skilled in the art.
  • One way to test the activity of the hybrid and/or single-chain meganuclease is to use an in vitro cleavage assay on a polynucleotide subtrat comprising the recognition and cleavage site corresponding to the assayed meganuclease.
  • Said polynucleotide substrat is a synthetic target site corresponding to the fusion of parental half sites which is synthesized and cloned into a vector. This vector, once linearized by a restriction enzyme, and then incubated with the hybrid.
  • Said polynucleotide substrat can be linear or circular and comprises preferably only one cleavage site.
  • the assayed meganuclease is incubated with the polynucleotide substrat in appropriate conditions.
  • the resulting polynucleotides are analyzed by any known method, for example by electrophoresis on agarose or by chromatography.
  • the meganuclease activity is detected by the apparition of two bands (products) and the disappearance of the initial full-length substrate band.
  • said assayed meganuclease is digested by poteinase K, for example, before the analysis of the resulting polynucleotides.
  • the target product is preparated with the introduction of a polynucleotide comprising the recognition and cleavage sequence in a plasmid by TA or restriction enzyme cloning, optionnally following by the linearization of the plamid.
  • a polynucleotide comprising the recognition and cleavage sequence in a plasmid by TA or restriction enzyme cloning, optionnally following by the linearization of the plamid.
  • such linearization is not done in the surrounding of the target site.
  • the recognition and cleavage of a specific DNA sequence by the hybrid and/or single-chain meganucleases according to the present invention can be assayed by any method known by the man skilled in the art.
  • One way to test the activity of the hybrid and/or single-chain meganuclease is to use an in vivo a Single-strand annealing recombination test (SSA). This kind of test is known by the man skilled in the art and disclosed for example in Rudin et al ( Genetics 1989, 122, 519-534); Fishman-Lobell & Haber ( Science 1992, 258, 480-4); Lin et al ( Mol. Cell. Biol., 1984, 4, 1020-1034) and Rouet et al ( Proc.
  • SSA Single-strand annealing recombination test
  • an in vivo assay based on SSA in an eukaryotic cell namely a yeast cell or a higher eukaryotic cell such as mammalian cells.
  • the method uses a yeast cell. This organism has the advantage recombine naturally its DNA via homologous recombination with a high frequency.
  • This in vivo test is based on the reparation by SSA of a reporter marker induced by site-specific double-stand break generated by the assayed meganuclease at its recognition and cleavage site.
  • the target consists of a modified reporter gene with an internal duplication separated by a intervening sequence comprising the recognition and cleavage site of the assayed meganuclease.
  • the internal duplication should contain at least 50 bp, preferably at least 200 bp, more preferably at least 300 or 400 bp.
  • the efficiency of the SSA test will be increased by the size of the internal duplication.
  • the intervening sequences at and preferably less than 2 kb.
  • the size of the intervening sequence which comprises least the recognition and cleavage site, is between few bp to 1 kb, more preferably among 500 bp.
  • the intervening sequence can optionally comprise a selection marker (for example, neomycin phosphotransferase, histidinol dehydrogenase, dihydrofolate reductase, hygromycin phosphotransferase, herpes simplex virus thymidine kinase, adenosine deaminase, glutamine synthetase, and hypoxanthine-guanine phosphoribosyl transferase for eukaryotic cell culture; TRP1 or URA3 for S.
  • a selection marker for example, neomycin phosphotransferase, histidinol dehydrogenase, dihydrofolate reductase, hygromycin phosphotransferase, herpes simplex virus th
  • reporter gene any nucleic acid encoding a product easily assayed, for example ⁇ -galactosidase, luciferase, alkaline phosphatase, green fluorescent protein, tyrosinase, DsRed proteins.
  • the reporter gene is preferably operably linked to a constitutive promoter relating to the cell used in the assay (for example CMV promoter). According to the present assay method, the reporter will be detected only if a SSA event occurs following the double-strand break introduced by the assayed meganuclease.
  • the assayed meganuclease is introduced in an expression cassette.
  • this expression cassette is on a separate construct.
  • the meganculease encoding sequence can be operably linked to an inducible promoter or to a constitutive promoter.
  • the promoter needs to be compatible with the cell used in the assay.
  • the construct is comprised by a plasmid.
  • each construct can comprise a selectable marker to ensure the presence of the plasmid in the cell.
  • the presence of this selectable marker is required for the asssay proceeded in yeast cell.
  • the first construct comprising the target gene can comprise a Leu2 selectable marker allowing transformed yeast to grow on a synthetic medium that does not contain any Leucine and the second construct can comprise the Trp1 selectable marker allowing transformed yeast to grow on a synthetic medium that does not contain any tryptophane.
  • the two constructs are used to transform simultaneously an appropriate cell. If the meganuclease is expressed and recognizes its cleavage site on the reporter construct, it can promote double-stand break and site-specific recombination between the target sequences by a mechanism known as Single-Strand Annealing. The resulting reporter gene should then express fully active reporter protein. Control experiments can be done with construct that does not express any meganuclease gene and reporter construct with no recognition and cleavage site.
  • the example 4 disclosed the use of a target consisting of a modified beta-galactosidase gene with a 900 pb internal duplication separated by the Ura3 selectable marker and a cleavage site for the assayed meganuclease (single-chain I-Cre I).
  • the recognition and cleavage by the hybrid and/or single-chain meganucleases according to the present invention can be also assayed with a gene convertion assay.
  • the reporter construct comprises a first modified reporter gene with a deletion and an insertion of an intervening sequence at the place of the deletion. This intervening sequence comprises the recognition and cleavage site of the assayed meganuclease.
  • the reporter construct further comprises the fragment of the reporter gene which has been deleted flanked at each side by the reporter gene sequences bordering the deletion.
  • the bordering sequences comprises at least 100 bp of homology with the reporter gene at each side, preferably at least 300 pb.
  • the recognition and cleavage by the hybrid and/or single-chain meganucleases according to the present invention can be assayed through a recombination assay on chromosomic target.
  • the recombination can be based on SSA or gene convertion mechanisms.
  • a mutated non-functional reporter gene comprising a recognition and cleavage site for the assayed meganuclease is introduced into the chromosome of the cell.
  • Said cleavage site has to be in the vicinity of the mutation, preferably at less than 1 kb from the mutation, more preferably at less than 500 bp, 200 bp, or 100 pb surrounding the mutation.
  • the present invention discloses new methods to discover novel targets for natural or hybrids of meganucleases in a targeted locus of a virus genome and other genomes of interest, more particularly in a gene thereof. Indeed, from the large number of LAGLIDADG meganuclease, the hybrid meganucleases allow to generate a high diversity of target sites. These new target sites are rare in the genome of interest, preferably almost unique, and are useful for several applications further detailed below.
  • a database comprising all known meganucleases target sites is prepared.
  • such database comprises the target sites that have been experimentally shown to be cleaved by a meganuclease.
  • a second database is designed comprising all possible targets for hybrid meganucleases. Such targets for hybrid meganucleases can be designed as disclosed above.
  • an alignment is done to find homologous sequences without gaps, said homologous sequences having an identity of at least 70%, preferably 80%, more preferably 90%, still more preferably 95%.
  • Various alignment algorithms and/or programs may be used to calculate the identity between two sequences, including FASTA, or BLAST which are available as a part of the GCG sequence analysis package (University of Wisconsin, Madison, Wis.), and can be used with, e.g., default settings.
  • the hybrid meganuclease according to the present invention can be used for molecular biology and for genetic engineering and gene therapy, more particularly according to the methods described in WO 96/14408, U.S. Pat. No. 5,830,729, WO 00/46385, WO 00/46386 and provisional application filed on 26/10/01 under Docket No. 3665-20 and on 14/03/01 under Docket No. 3665-17; the disclosure of these documents being incorporated by reference.
  • hybrid meganuclease A very interesting use of the hybrid meganuclease is for targeting a particular genomic locus of interest. Indeed, the induction of a double stranded break at a site of interest in chromosomal DNA of the cell is accompanied by the introduction of a targeting DNA homologous to the region surrounding the cleavage site with a high efficient.
  • the hybrid meganuclease can be used for targeting a particular genomic locus comprising the hybrid target site.
  • Hybrid meganucleases according to the present invention can be used in methods involving the induction in cells of double stranded DNA cleavage at a specific site in chromosomal DNA. For more detailed, see WO 96/14408, U.S. Pat. No.
  • the hybrid meganuclease can be used in a method of genetic engineering comprising the following steps: 1) introducing a double-stranded break at the genomic locus comprising the hybrid target site with the corresponding hybrid meganuclease; 2) providing a targeting DNA construct comprising the sequence to introduce flanked by homologous sequence to the targeting locus.
  • the homologous DNA is at the left and right arms of the targeting DNA construct and the DNA which modifies the sequence of interest is located between the two arms.
  • Said hybrid meganuclease can be provided to the cell either through an expression vector comprising the polynucleotide sequence encoding said hybrid meganuclease and suitable for its expression in the used cell or the hybrid meganuclease itself.
  • the hybrid or single chain meganucleases according to the present invention can be used for the deletion of a viral genome or a part thereof. Indeed, a cut in the viral genome induces a recombination that can lead to the deletion of a part or the whole viral genome deletion. This method is generally called virus pop-out. Therefore, the hybrid meganucleases allow the targeting of the viral genome. See WO 96/14408 example 5. Therefore, the invention concerns a method of deleting a viral genome or a part thereof, wherein a double-strand break in the viral genome is induced by a meganuclease according to the present invention and said double-strand break induces a recombination event leading to the deletion of the viral genome or a part thereof.
  • hybrid and single chain meganucleases can be for in vivo excision of a polynucleotide fragment flanked by at least one, preferably two, hybrid target site.
  • Hybrid meganucleases according to the present invention can be used in methods involving the excision of targeting DNA or polynucleotide fragment from a vector within cells which have taken up the vector.
  • Such methods involve the use of a vector comprising said polynucleotide fragment flanked by at least one, preferably two, hybrid target site and either an expression vector comprising a polynucleotide encoding the hybrid and single chain meganuclease corresponding to the hybrid target site suitable for the expression in the used cell, or said hybrid and single chain meganuclease.
  • Said excised polynucleotide fragment can be used for transgenesis as described in detail in provisional application filed on 26/10/01 under U.S. Ser. No. 60/330,639 and on 14/03/01 under U.S. Ser. No. 60/318,818.
  • Said excised targeting DNA comprises homologous DNA at the left and right arms of the targeting DNA and the DNA which modifies the sequence of interest is located between the two arms.
  • Said method of excision of targeting DNA from a vector within the cell can be used for repairing a specific sequence of interest in chromosomal DNA, for modifying a specific sequence or a gene in chromosomal DNA, for attenuating an endogeneous gene of interest, for introducing a mutation in a target site, or for treating or prohylaxis of a genetic disease in an individual.
  • the present invention also relates to the resulting cells and to their uses, such as for production of proteins or other gene products or for treatment or prophylaxis of a condition or disorder in an individual (e.g. a human or other mammal or vertebrate) arising as a result of a genetic defect (mutation).
  • an individual e.g. a human or other mammal or vertebrate
  • a genetic defect e.g. a genetic defect (mutation).
  • cells can be produced (e.g., ex vivo) by the methods described herein and then introduced into an individual using known methods.
  • cells can be modified in the individual (without being removed from the individual).
  • the invention also relates to the generation of animal models of disease in which hybrid meganuclease sites are introduced at the site of the disease gene for evaluation of optimal delivery techniques.
  • I-DmoI is a thermostable endonuclease encoded by an intron in the 23S rRNA gene of the hyperthermophilic archaeon Desulfrrococcus mobilis (Dalgaard et al., 1993, Proc Natl Acad Sci USA, 90, 5414-5417).
  • I-DmoI belongs to the LAGLIDADG family of meganucleases. Its structure, solved by X-ray crystallography (pdb code 1b24) (Silva et al., 1999, J Mol Biol, 286, 1123-1136), consists of two similar ⁇ / ⁇ domains ( ⁇ ) related by pseudo two-fold symmetry.
  • a dodecapeptide motif is located at the C-terminal end of the first ⁇ -helix in each domain. These helices form a two-helix bundle at the interface between the domains and are perpendicular to a saddle-shaped DNA binding surface formed by two four-stranded antiparallel ⁇ -sheets ( FIG. 1 ).
  • I-CreI is another LAGLIDADG meganuclease, encoded by an open reading frame contained within a self-splicing intron in the Chlamydomonas reinhardtii chloroplast 23S rRNA gene (Durrenberger and Rochaix, 1991, Embo J, 10, 3495-3501). However, unlike most members of this protein family, I-CreI contains a single copy of the dodecapeptide motif, and functions in a dimeric form. I-CreI dimers display the overall architecture of single chain LAGLIDADG proteins ( FIG.
  • Each monomer corresponds to a single domain, providing one of the two four-stranded antiparallel ⁇ -sheets for DNA-binding, and the dodecapeptide motifs are within ⁇ -helices at the inter-domain interface.
  • I-DmoI and I-CreI can be superimposed to low (local) root mean square deviation (RMSD), each monomer from I-CreI finely matching one of the two domains from I-DmoI.
  • RMSD root mean square deviation
  • the low RMSD is a strong indication of the similarity of the two dodecapeptide inter-domain packing interfaces.
  • the dodecapeptide motifs and corresponding ⁇ -helices aligned sequences are: Motifs Sequences I-DmoI, 1 st dodecapeptide ⁇ -helix SGISAY 13 LLGLIIGDG I-DmoI, 2 nd dodecapeptide ⁇ -helix EQIAF 109 IKGLYVAEG I-CreI, dodecapeptide ⁇ -helix (1 st NKEFLLY 12 LAGFVDGDG monomer) I-CreI, dodecapeptide ⁇ -helix (2 nd NKEFLLY 212 LAGFVDGDG monomer)
  • the novel inter-domain packing interface presented only little defects, e.g. no amino acid side chain has steric clashes that should not easily relax, except perhaps for Ile107 (I-DmoI) that has overlaps with Phe294 (I-CreI).
  • I-DmoI Ile107
  • I-CreI Phe294
  • the isoleucine residue is replaced by a leucine amino acid (the aligned amino acid residue in I-CreI).
  • the inter-domain linker sequence is as follows: I-DmoI Linker (I-DmoI) I-CreI (N-term) . . . YYFA NMLERIRLFNMREQLAF LAGF . . . (C-term) SEQ ID NO 7
  • Sonication solution 25 mM HEPES (pH 7.5), 5% (v/v) glycerol, 0,1% (v/v) anti-proteases solution;
  • Solution A 25 mM HEPES (pH 7.5), 5% (v/v) glycerol,
  • Standard reaction solution 12,5 mM HEPES (pH 7.5), 2,5% (v/v) glycerol, 5-10 mM MgCl 2 ;
  • An expression plasmid (pET 24 d(+) Novagen) was engineered to produce I-DmoI/I-CreI hybrid meganuclease with or without an histidin tag. Briefly, a fragment containing the ORF sequence and flanked by NcoI and EagI or XhoI restriction sites was prepared using the polymerase chain reaction (PCR) and specific oligonucleotides. Firstly, the half I-DmoI and I-CreI sequences were prepared by PCR then I-DmoI/I-CreI hybrid sequence was completed by another PCR.
  • PCR polymerase chain reaction
  • Escherichia coli strain BL21(DE3) RIL was used for the purification of I-DmoI/I-CreI.
  • Clones transformed with the I-DmoI/I-CreI plasmid (pET 24 d(+) Novagen) were grown in 250 ml of Luria Broth containing 30 mg/ml kanamycin at 37° C. with shaking. When the culture reached an A 600 of 0.8-1.2, expression was induced by adding IPTG to a final concentration of 1 mM, and after 5 h to 15 h at 25° C., the cells were harvested by centrifugation.
  • the harvested cells were resuspended in 25 ml of ice-cold sonication solution, and then sonicated for 5 minutes.
  • the lysate was centrifuged at 105 000 g for 30 min.
  • the supernatant recovered, and then subjected to a second ultracentrifugation at 105 000 g for 30 min. This supernatant, which contained 90% of the protein, was called the ‘soluble’ fraction.
  • the soluble fraction was applied to a 5 ml Hi-Trap chelating column (Amersham, Uppsala, Sweden) load with cobalt at a flow rate of 2,5 ml/min (Amersham-Pharmacia FPLC Akta purifier 10). After washing the column with 25 ml of solution A, bound proteins were eluted with a 0-0.25 M linear immidazole gradient made up in solution A following by an elution step at 0,5M immidazole-0,5M NaCl. Fractions were collected, and the amounts of protein and I-DmoI/I-CreI activity (see below) were determined. The column fractions were also analyzed by SDS-PAGE.
  • the fractions containing most of the I-DmoI/I-CreI activity were pooled and concentrated using a 10 kDa cut-off centriprep Amicon system. This concentrated fraction was purified was applied to a Superdex75 PG Hi-Load 26-60 column (Amersham, Uppsala, Sweden) at a flow rate of 1 ml/min (Amersham-Pharmacia FPLC Akta purifier 10) of solution A. Fractions were collected, and the amounts of protein and I-DmoI/I-CreI activity (see below) were determined. The column fractions were also analyzed by SDS-PAGE.
  • the fractions containing most of the I-DmoI/I-CreI activity were pooled and concentrated using a 10 kDa cut-off centriprep Amicon system. Then dialysed against storage solution over-night, and stored in aliquots in liquid nitrogen.
  • SDS-polyacrylamide gel electrophoresis SDS-PAGE was performed as described by Laemmli using 15% acrylamide gels. Gels were stained with coomassie brilliant blue.
  • FIG. 8A shows that the hybrid meganuclease I-DmoI/I-CreI is well expressed and that this hybrid is obtained in the supernatant and therefore is soluble.
  • the molecular weight of I-DmoI/I-CreI in solution was estimated by size-exclusion chromatography of the purified protein.
  • the column fractions were analyzed by SDS-PAGE, and the 31,2 kDa band eluted primarily, which corresponded to a molecular mass of 30 kDa.
  • this analysis indicated that I-DmoI/I-CreI is mainly a momomer.
  • I-CreI is a single LAGLIDADG protein domain that dimerizes ( FIG. 2 ).
  • domain swapping strategy we planned to connect an I-CreI domain to any other LAGLIDADG domain.
  • Each I-CreI domain comprises a C-terminal sub-domain made of three ⁇ -helices, which may be present in the C-terminal domain of double LAGLIDADG proteins, but cannot be part of the N-terminal domain.
  • the N-terminal domain of these proteins is indeed shorter, as the loop or linker connecting the two domains stands in place of the three ⁇ -helices.
  • the three helices terminate at opposite sides of the dimer structure, far away from the N-terminal helices of the dodecapeptide motifs.
  • the length of a flexible linker connecting the C-terminal residue of one domain to the N-terminal residue of the other domain (end-to-end fusion) would be considerable. Besides, engineering such linker would be difficult due to the necessity to go across a large part of the protein surface. Therefore, it is uncertain that proper domain packing be obtained.
  • residues from I-DmoI and I-CreI can be well aligned and superimposed.
  • Source Target Atoms residues Sequence residues Sequence superimposed I-DmoI, N ML I-CreI, P FL N, C ⁇ , C, O 93-95 93-95 I-DmoI, REQ I-CreI, KEF N, C ⁇ , C, O 104-106 207-209
  • the link between the I-CreI domains should thus be chosen to replace the C-terminal residues of the first domain and the N-terminal residues of the second, respectively from either Pro93, Phe94 or Leu95 and up to Lys207, Glu208 or Phe209.
  • amino acids at two of the superimposed positions are identical (Leu95 in both proteins and Glu105 from I-DmoI with Glu208 from I-CreI; underlined residues), and at a third position they are sufficiently similar to be equivalent (Arg104 and Lys207 from I-DmoI and I-CreI, respectively; underlined residues).
  • the lysine 98 of the first domain I-CreI has been removed despite of the disclosure of Jurica et al (1998, Mol. Cell., 2, 469-476) saying that Lysine 98 in I-CreI which is a well-conserved residue and is close to the active (cleavage) site could have a functional role.
  • Proline 93 is not an optimal residue for the ⁇ -helical conformation of the main chain at that residue position.
  • the corresponding asparagine in I-DmoI is only slightly better; particular hydrogen bonding properties of the amino acid establish a pronounced tendency to promote a N-terminal break in ⁇ -helices.
  • an alanine residue is eventually preferred (glutamic acid would be another suitable amino acid, which has good intrinsic propensity to adopt a ⁇ -helical conformation and could form a stabilizing salt-bridge with Arg97 in the following linker region).
  • I-CreI A single chain version of I-CreI was thus engineered so as to introduce the I-DmoI bridge, starting with Met94 and up to Glu105, between a shortened version of the natural I-CreI domain (truncation after the Pro93Ala mutation) and a nearly complete copy of that domain (truncation before Phe209) ( FIG. 5 and FIG. 7 for the amino acid (SEQ ID No. 6) and polynucleotide sequences (SEQ ID No. 5)).
  • Met94 replaced a bulkier phenylalanine amino acid that is buried into the I-CreI protein dimer. Both amino acids appear to fit equally well, and could be tried alternatively at that sequence position.
  • I-CreI Linker I-CreI (N-term) . . . TQLQ AMLERIRLFNMR EFLL . . . (C-term) (SEQ ID N0 8) (N-term) . . .
  • TQLQ AFLERIRLFNMR EFLL . . . (C-term) (SEQ ID N0 9) (N-term) . . . TQLQ AMLERIRLYNMR EFLL . . . (C-tenn) (SEQ ID N0 10) (N-term) . . . TQLQ AFLERIRLYNMR EFLL . . . (C-term) (SEQ ID N0 11)
  • Sonication solution 25 mM HEPES (pH 7.5), 5% (v/v) glycerol, 0,1% (v/v) anti-proteases solution;
  • Solution A 25 mM HEPES (pH 7.5), 5% (v/v) glycerol,
  • Standard reaction solution 12,5 mM HEPES (pH 7.5), 2,5% (v/v) glycerol, 5-10 mM MgCl 2 ;
  • An expression plasmid (pET 24 d(+) Novagen) was engineered to produce Single chain I-CreI (Sc I-CreI) with or without an histidine tag. Briefly, a fragment containing the ORF sequence and flanked by NcoI and EagI or XhoI restriction sites was prepared using the polymerase chain reaction (PCR) and specific oligonucleotides. Firstly, the two half modified I-CreI sequences were prepared by PCR then the single chain I-CreI hybrid sequence was completed by another PCR.
  • PCR polymerase chain reaction
  • Escherichia coli strain BL21(DE3) RIL was used for the production and the purification of Sc I-CreI polypeptide.
  • Clones transformed with the Sc I-CreI plasmid (pET 24 d(+) Novagen) were grown in 250 ml of Luria Broth containing 30 mg/ml kanamycin at 37° C. with shaking.
  • the harvested cells were resuspended in 25 ml of ice-cold sonication solution, and then sonicated for 5 minutes.
  • the lysate was centrifuged at 105 000 g for 30 min.
  • the supernatant recovered, and then subjected to a second ultracentrifugation at 105 000 g for 30 min. This supernatant, which contained 90% of the protein, was called the ‘soluble’ fraction.
  • the soluble fraction was applied to a 5 ml Hi-Trap chelating column (Amersham, Uppsala, Sweden) load with cobalt at a flow rate of 2,5 ml/min (Amersham-Pharmacia FPLC Akta purifier 10). After washing the column with 25 ml of solution A, bound proteins were eluted with a 0-0.25 M linear immidazole gradient made up in solution A following by an elution step at 0,5M immidazole-0,5M NaCl. Fractions were collected, and the amounts of protein and Sc I-CreI activity (see below) were determined. The column fractions were also analyzed by SDS-PAGE.
  • the fractions containing most of the Sc I-CreI activity were pooled and concentrated using a 10 kDa cut-off centriprep Amicon system. This concentrated fraction was purified was applied to a Superdex75 PG Hi-Load 26-60 column (Amersham, Uppsala, Sweden) at a flow rate of 1 ml/min (Amersham-Pharmacia FPLC Akta purifier 10) of solution A. Fractions were collected, and the amounts of protein and Sc I-CreI activity (see below) were determined. The column fractions were also analyzed by SDS-PAGE.
  • the fractions containing most of the Sc I-CreI activity were pooled and concentrated using a 10 kDa cut-off centriprep Amicon system. Then dialysed against storage solution over-night, and stored in aliquots in liquid nitrogen.
  • SDS-polyacrylamide gel electrophoresis SDS-PAGE was performed as described by Laemmli using 15% acrylamide gels. Gels were stained with coomassie brilliant blue. ( FIG. 9A )
  • the molecular weight of Sc I-CreI in solution was estimated by size-exclusion chromatography of the purified protein.
  • the results of the sizing column are summarized in FIG. 2A .
  • the column fractions were analyzed by SDS-PAGE, and the 31,4 kDa band eluted primarily, which corresponded to a molecular mass of 30 kDa.
  • this analysis indicated that Sc I-CreI is mainly a momomer.
  • Plasmid pGEMtarget (3.9 kb), was constructed by TA or restriction enzyme cloning of the target product, obtained by PCR or single strain hybridation.
  • the target products comprise the following recognition and cleavage sites: wild type I-Cre I CAAAACGTCGT GAGACAGTTTGGTCCA SEQ ID N0 12 wild type I-Dmo I CCTTGCCGGGT AAGTTCCGGCGCGCAT SEQ ID N0 13 L (I-Dmo I) /R (I-Cre I) target CCTTGCCGGGT GAGACAGTTTGGTCCA SEQ ID N0 14 L (I-cre I) /R (I-Dmo I) target CAAAACGTCGT AAGTTCCGGCGCGCAT SEQ ID N0 15
  • This plasmid was used for the cleavage assays. It was isolated with the Quiagen Maxipreps DNA Purification System (Qiagen). For most experiments, it was linearized with XmnI prior to the assay. Standard I-DmoI/I-CreI assays were performed at 37° C. in the standard reaction solution (solution A 0.5 ⁇ , add MgCl 2 5 to 10 mM), stopped with 0.1 vol of 10 ⁇ standard stop solution, and the products separated by electrophoresis in 1% agarose/ethidium bromide gels at room temperature. The fluorescence was captured with camera using a transilluminator.
  • One unit of endonuclease activity was defined as the amount of I-DmoI/I-CreI necessary to cleave 200 ng of target DNA in 60 min at 37° C. in the same assay condition than I-CreI wild-type. Activity assays were also performed at 65° C. as I-DmoI optimal temperature for DNA cleavage.
  • the I-DmoI/I-CreI hybrid meganuclease specifically cleaves the target I-CreI/I-DmoI and does not cleave the wild type targets of I-Dmo I, I-Cre I, and I-Sce I meganucleases and the target I-DmoI/I-Cre L. These results are shown in FIG. 8B . Thus, the I-DmoI/I-CreI hybrid meganuclease shows a high specificity for its new target sequence.
  • the I-DmoI/I-CreI hybrid meganuclease cleaves the target I-CreI/I-DmoI at 37 and 65° C., but the cleavage is more rapid at 65° C.
  • the new specificity of the I-DmoI/I-CreI hybrid meganuclease for the target I-CreI/I-DmoI allows the determination of the relative orientation of the wild type meganuclease I-Dmo I and its recognition and cleavage site. Indeed, the N-terminal domain of I-Dmo I meganuclease recognizes the second half domain of the target I-CreI/I-DmoI. Therefore, the N-terminal domain of I-Dmo I meganuclease recognize the right half site (R) and its C-terminal domain the left one (L).
  • Plasmid pGEMtarget (3.9 kb), was constructed by TA or restriction enzyme cloning of the target product, obtained by PCR or single strain hybridation.
  • the target product comprises the recognition and cleavage site wild type CAAAACGTCGT GAGACAGTTTTGGTCCA SEQ ID N0 12 I-Cre I wild type TAGGGAT AACAGGGTAAT SEQ ID N0 16 I-Sce I
  • This plasmid was used for the cleavage assays. It was isolated with the Quiagen Maxipreps DNA Purification System (Qiagen). For most experiments, it was linearized with XmnI prior to the assay. Standard Sc I-CreI assays were performed at 37° C. in the standard reaction solution (solution A 0.5 ⁇ , add MgCl 2 5 to 10 mM), stopped with 0.1 vol of 10 ⁇ standard stop solution, and the products separated by electrophoresis in 1% agarose/ethidium bromide gels at room temperature. The fluorescence was captured with camera using a transilluminator.
  • One unit of endonuclease activity was defined as the amount of Sc I-CreI necessary to cleave 200 ng of target DNA in 60 min at 37° C. in the same assay condition than I-CreI wild-type. Activity assays were also performed at 65° C. to compare with the wild type I-CreI about effect of temperature on DNA cleavage.
  • the single chain meganuclease kept its specificty as this meganuclease did not cleave the I-Sce I target site and cleaved the wild type I-Cre I target site. These results are shown in FIG. 9B .
  • This test was based on the reparation of a colorimetric marker induced by site-specific double-stand break by the meganuclease of interest.
  • the target consisted of a modified beta-galactosidase gene with a 900 pb internal duplication separated by the Ura3 selectable marker and a cleavage site for the meganuclease to be studied (the resulting construct has been called LACURAZ) ( FIG. 10A ).
  • the meganuclease was expressed under the control of a galactose-inducible promoter from a nuclear expression plasmid which carried the Leu2 selectable marker allowing transformed yeast to grow on a media that do not contain any Leucine, and a 21 origin of replication ( FIG. 10B ).
  • the expression of the reporter gene (LACURAZ) was controled by a constitutive promoter and was carried by another shuttle vector with the Trp1 selectable marker allowing transformed yeast to grow on a media that did not contain any tryptophane and an ARS-CEN origin of replication ( FIG. 10A ).
  • the two constructs were used to transform simultaneously an appropriate yeast strain. If the meganuclease is expressed (or overexpressed after induction on a galactose media) and recognizes its cleavage site on the reporter construct, it can promote double-stand break and site-specific recombination between the target sequences by a Single-Strand Annealing mechanism. The resulting reporter gene should then express fully active beta-galatosidase. We also prepared all the control expeminents with plasmids that do not express any meganuclease gene and reporter construct with no cleavage site (all the possible event are described in FIG. 11 ).
  • the assay is performed as follow:
  • the yeast was co-transfected with the expression plasmid and the reporter plasmid.
  • the co-transformants were selected, and the presence of the two plasmids was achieved by selection on a synthetic media containing no Leucine nor Tryptophane (Table A).
  • two sets of media were used allowing the overexpression of the meganuclease gene or not (i.e. on selective media with different carbone source: galactose to induce the expression of the meganuclease or glucose).
  • an overlay assay revealed the presence or abscence of the beta-galactosidase activity.
  • beta-galactosidase activity should only be detected when a meganuclease and its own recongnition site are present in the same yeast cell (except the natural background of autonomous recombination of the reporter construct) (see FIG. 10 ).
  • the basic “transformation mix” consists of:
  • Colonies may be picked through the top agar even 5 days later. Just take a sterile Pasteur pipette and poke it through the agar into the desired colony or patch. Then use the tip of the Pasteur pipette to streak a fresh plate and, despite the permeabilization, the cells will grow up.
  • the Single-chain I-CreI gene allows the expression of an active meganuclease that behaves like the natural I-CreI molecule by recognizing and cutting its own cleavage site inducing homologous recombinaison of the reporter sequence.
  • the light blue color is due to a very small expression of the meganuclease which is very stable in the cell.
  • This small amount of protein allows the reporter construct to recombine leading to the production of a detectable ⁇ -galactosidase activity.
  • On every “white” plate some blue colonies appear at an average rate of 10 ⁇ 2 . This background is due to the high spontaneous recombination in yeast.
  • the reporter plasmid was cotransfected into simian COS cells, with 0.5 ⁇ g of pCLS3.1, 0.5 ⁇ g of the I-CreI expressing plasmid, or 0.5 ⁇ g of the single-chain I-CreI expressing plasmid.
  • the beta-galactosidase activity was monitored 72 hours after transfection by an assay described below.
  • a reporter plasmid without any cleavage site was cotransfected with 0.5 ⁇ g of pCLS3.1, 0.5 ⁇ g of the I-CreI expressing plasmid, or 0.5 ⁇ g of the single-chain I-CreI expressing plasmid.
  • This assay is based on the detection of tandem repeat recombination, which often occurs by a process referred to as SSA (Single-strand Annealing). Therefore, we also designed an assay based on the detection of recombination between inverted repeats. Recombination between inverted repeats mostly occurs by gene conversion, another kind of recombination event.
  • a complete LacZ ORF, interrupted by an I-CreI cleavage site (and thus not functional) is introduced into pcDNA3, between the CMV promoter and the termination sequence.
  • a truncated non functional copy of the gene is cloned in an inverted orientation, to provide an homologous donor template for gene conversion. It is not flanked by promoter and terminator sequences. It encompasses 2.5 Kb of the inner part of the LacZ ORF, overlapping the region where the I-CreI cleavage site is found in the other copy.
  • 0.5 ⁇ g of the reporter plasmid was cotransfected into COS cells, with 0.5 ⁇ g of pCLS3.1, 0.5 ⁇ g of the I-CreI expressing plasmid, or 0.5 ⁇ g of the single-chain I-CreI expressing plasmid.
  • 0.5 ⁇ g of a reporter plasmid without any homologous donor template was cotransfected with 0.5 ⁇ g of pCLS3.1, 0.5 ⁇ g of the I-CreI expressing plasmid, or 0.5 ⁇ g of the single-chain I-CreI expressing plasmid.
  • the assay is performed as follow:
  • COS cells were transfected with Effectene transfection reagent accordingly to the supplier (Qiagen) protocol. 72 hours after transfection, cells were rinsed twice with PBS1X and incubated in lysis buffer (Tris-HCl 10 mM pH7.5, NaCl 150 mM, Triton X100 0,1%, BSA 0.1 mg/ml, protease inhibitors). Lysate was centrifuged and the supernatant used for protein concentration determination and ⁇ -galactosidase liquid assay.
  • lysis buffer Tris-HCl 10 mM pH7.5, NaCl 150 mM, Triton X100 0,1%, BSA 0.1 mg/ml, protease inhibitors
  • NAR 27 4167-74 (525) PI-PfuII Pfu RIR1-2 Pyrococcus furiosus 383 DD 1999 Komori, et al. NAR 27: 4167-74 PI-PfuIII Pfu RtcB, Pfu rtcB4 Pyrococcus furiosus 481 DD (Pfu Hyp-2) PI-PfuIV Pfu RIR1-1 Pyrococcus furiosus 455 DD PI-PfuIX Pfu RFC Pyrococcus furiosus 525 DD PI-PfuV Pfu IF2 Pyrococcus furiosus 387 DD PI-PfuVI Pfu lon Pyrococcus furiosus 401 DD PI-PfuVII Pfu CDC21 Pyrococcus furiosus 367 DD PI-PfuVIII Pfu VMA Pyrococcus furiosus 424 DD PI-PfuX Pfu topA Py
  • JBC 275: 2335-41 Pyrococcus PI-TfuII Tfu pol-2 Thermococcus fumicolans 389 DD Z69882 2000 Saves, et al. JBC 275: 2335-41 ( Pyrococcus ) PI-ThyI Thy pol-1 Thermococcus hydrothermalis 538 DD ( Pyrococcus ) PI-ThyII Thy pol-2 Thermococcus hydrothermalis 390 DD 2001 http://bioinformatics.weizmann.ac.il/ ⁇ pietro/inteins ( Pyrococcus ) PI-Tll I Tli pol-2, pl-TliIR Thermococcus litoralis 390 DD M74198 1992 Perler et al.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Detergent Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
US10/507,736 2002-03-15 2003-03-14 Hybrid and single chain meganucleases and use thereof Abandoned US20060078552A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US10/507,736 US20060078552A1 (en) 2002-03-15 2003-03-14 Hybrid and single chain meganucleases and use thereof
US12/482,124 US20100151556A1 (en) 2002-03-15 2009-06-10 Hybrid and single chain meganucleases and use thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36411302P 2002-03-15 2002-03-15
PCT/IB2003/001352 WO2003078619A1 (fr) 2002-03-15 2003-03-14 Meganucleases hybrides et monocatenaires et leur utilisation
US10/507,736 US20060078552A1 (en) 2002-03-15 2003-03-14 Hybrid and single chain meganucleases and use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2008/001331 Continuation-In-Part WO2009095742A1 (fr) 2002-03-15 2008-01-31 Nouvelle méganucléase à chaîne unique dérivée de l'i-crei et ses utilisations

Publications (1)

Publication Number Publication Date
US20060078552A1 true US20060078552A1 (en) 2006-04-13

Family

ID=28041871

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/507,736 Abandoned US20060078552A1 (en) 2002-03-15 2003-03-14 Hybrid and single chain meganucleases and use thereof
US10/388,230 Expired - Fee Related US8206965B2 (en) 2002-03-15 2003-03-14 Hybrid and single chain meganucleases and use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
US10/388,230 Expired - Fee Related US8206965B2 (en) 2002-03-15 2003-03-14 Hybrid and single chain meganucleases and use thereof

Country Status (10)

Country Link
US (2) US20060078552A1 (fr)
EP (1) EP1485475B2 (fr)
JP (3) JP2005520519A (fr)
AT (1) ATE372379T1 (fr)
AU (1) AU2003215869B2 (fr)
CA (1) CA2479153C (fr)
DE (1) DE60316124T3 (fr)
DK (1) DK1485475T3 (fr)
ES (1) ES2292994T3 (fr)
WO (1) WO2003078619A1 (fr)

Cited By (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090111119A1 (en) * 2007-09-27 2009-04-30 Yannick Doyon Rapid in vivo identification of biologically active nucleases
WO2009134714A3 (fr) * 2008-04-28 2010-01-28 Precision Biosciences, Inc. Molécules de fusion de protéines de liaison à l'adn et de domaines effecteurs conçus de façon rationnelle
US20100021448A1 (en) * 2005-03-15 2010-01-28 Cellectis I-crei meganuclease variants with modified specificity, method of preparation and uses thereof
WO2009114321A3 (fr) * 2008-03-11 2010-02-04 Precision Biosciences, Inc. Méganucléases rationnellement conçues pour modification par génie génétique du génome du maïs
US20100071083A1 (en) * 2008-03-12 2010-03-18 Smith James J Temperature-dependent meganuclease activity
WO2010107493A2 (fr) 2009-03-20 2010-09-23 Sangamo Biosciences, Inc. Modification de cxcr4 en utilisant des protéines à doigt de zinc modifiées
WO2010093966A3 (fr) * 2009-02-12 2010-10-14 Fred Hutchinson Cancer Research Center Génération d'une enzyme de césure de l'adn stimulant la conversion d'un gène spécifique d'un site à partir d'une endonucléase de ciblage
US20100311817A1 (en) * 2007-10-31 2010-12-09 Smith James J Rationally-designed single-chain meganucleases with non-palindromic recognition sequences
US20110014616A1 (en) * 2009-06-30 2011-01-20 Sangamo Biosciences, Inc. Rapid screening of biologically active nucleases and isolation of nuclease-modified cells
US20110033935A1 (en) * 2007-12-07 2011-02-10 Precision Biosciences, Inc. Rationally-designed meganucleases with recognition sequences found in dnase hypersensitive regions of the human genome
US20110041195A1 (en) * 2009-08-11 2011-02-17 Sangamo Biosciences, Inc. Organisms homozygous for targeted modification
EP2327774A2 (fr) 2005-10-18 2011-06-01 Precision Biosciences Méganucléases conçues rationnellement possédant une spécificité de séquence modifiée et une affinité de liaison modifiée pour L'ADN
US20110129898A1 (en) * 2009-05-18 2011-06-02 Yannick Doyon Methods and compositions for increasing nuclease activity
EP2336329A1 (fr) 2007-06-01 2011-06-22 Omt, Inc. Compositions et procédés pour inhiber des gênes d' immunoglobuline endogènes et produire des anticorps d'idiotype humain transgéniques
US20110173710A1 (en) * 2007-12-13 2011-07-14 Cellectis Chimeric meganuclease enzymes and uses thereof
US20110202479A1 (en) * 2008-07-14 2011-08-18 Derek Jantz Recognition sequences for i-crei-derived meganucleases and uses thereof
US20110207199A1 (en) * 2007-08-03 2011-08-25 Cellectis Novel method to generate meganucleases with altered characteristics
US20110225664A1 (en) * 2008-09-08 2011-09-15 Cellectis Meganuclease variants cleaving a dna target sequence from a glutamine synthetase gene and uses thereof
WO2013130824A1 (fr) 2012-02-29 2013-09-06 Sangamo Biosciences, Inc. Procédés et compositions permettant de traiter la maladie de huntington
US8563314B2 (en) 2007-09-27 2013-10-22 Sangamo Biosciences, Inc. Methods and compositions for modulating PD1
WO2014059173A2 (fr) 2012-10-10 2014-04-17 Sangamo Biosciences, Inc. Composés modifiant les lymphocytes t et leurs utilisations
EP2727600A1 (fr) 2009-07-28 2014-05-07 Sangamo BioSciences, Inc. Procédés et compositions pour le traitement de maladies à répétition trinucléotidique
US8802437B2 (en) 2009-09-24 2014-08-12 Cellectis Meganuclease reagents of uses thereof for treating genetic diseases caused by frame shift/non sense mutations
WO2015070212A1 (fr) 2013-11-11 2015-05-14 Sangamo Biosciences, Inc. Méthodes et compositions pour traiter la maladie de huntington
US9044492B2 (en) 2011-02-04 2015-06-02 Cellectis Sa Method for modulating the efficiency of double-strand break-induced mutagenesis
US9365864B2 (en) 2008-10-23 2016-06-14 Cellectis Meganuclease recombination system
WO2016161446A1 (fr) 2015-04-03 2016-10-06 Dana-Farber Cancer Institute, Inc. Composition et procédés de correction génomique de cellules b
EP3156062A1 (fr) 2010-05-17 2017-04-19 Sangamo BioSciences, Inc. Nouvelles protéines à liaison adn et leurs utilisations
WO2017106528A2 (fr) 2015-12-18 2017-06-22 Sangamo Biosciences, Inc. Disruption ciblée du récepteur des lymphocytes t
WO2017106537A2 (fr) 2015-12-18 2017-06-22 Sangamo Biosciences, Inc. Disruption ciblée du récepteur des cellules du cmh
WO2018039448A1 (fr) 2016-08-24 2018-03-01 Sangamo Therapeutics, Inc. Nucléases spécifiques de cible spécifiquement modifiées
WO2018058002A1 (fr) 2016-09-23 2018-03-29 Fred Hutchinson Cancer Research Center Tcr spécifiques de l'antigène ha-1 d'histocompatibilité (h) mineure et ses utilisations
WO2018204469A2 (fr) 2017-05-03 2018-11-08 Sangamo Therapeutics, Inc. Méthodes et compositions pour la modification d'un gène régulateur de la conductance transmembranaire de la mucoviscidose (cftr)
WO2018218038A1 (fr) 2017-05-24 2018-11-29 Effector Therapeutics, Inc. Méthodes et compositions d'immunothérapie cellulaire
WO2019051128A1 (fr) 2017-09-06 2019-03-14 Fred Hutchinson Cancer Research Center Récepteurs chimériques spécifiques d'étiquette strep et utilisations de ceux-ci
WO2019051135A1 (fr) 2017-09-06 2019-03-14 Fred Hutchinson Cancer Research Center Méthodes pour améliorer une thérapie cellulaire adoptive
WO2019079777A1 (fr) 2017-10-20 2019-04-25 Fred Hutchinson Cancer Research Center Compositions et procédés d'immunothérapie ciblant tigit et/ou cd112r ou comprenant la surexpression de cd226
WO2019109047A1 (fr) 2017-12-01 2019-06-06 Fred Hutchinson Cancer Research Center Protéines de liaison spécifiques à 5t4 et leurs utilisations
WO2019140278A1 (fr) 2018-01-11 2019-07-18 Fred Hutchinson Cancer Research Center Immunothérapie ciblant des antigènes du facteur de liaison du noyau
WO2019165116A1 (fr) 2018-02-26 2019-08-29 Fred Hutchinson Cancer Research Center Compositions et méthodes pour immunothérapie cellulaire
WO2020018964A1 (fr) 2018-07-20 2020-01-23 Fred Hutchinson Cancer Research Center Compositions et procédés pour réguler l'expression de récepteurs spécifiques à l'antigène
WO2020041501A1 (fr) 2018-08-22 2020-02-27 Fred Hutchinson Cancer Research Center Immunothérapie ciblant les antigènes kras ou her2
WO2020047099A1 (fr) 2018-08-28 2020-03-05 Fred Hutchinson Cancer Research Center Procédés et compositions pour thérapie adoptive par lymphocytes t comportant une signalisation notch induite
WO2020068702A1 (fr) 2018-09-24 2020-04-02 Fred Hutchinson Cancer Research Center Protéines de récepteur chimérique et leurs utilisations
WO2020097530A2 (fr) 2018-11-09 2020-05-14 Fred Hutchinson Cancer Research Center Immunothérapie ciblant la mésothéline
EP3665191A1 (fr) 2017-08-11 2020-06-17 Fred Hutchinson Cancer Research Center Tcr de braf spécifiques et utilisations associées
WO2020172332A1 (fr) 2019-02-20 2020-08-27 Fred Hutchinson Cancer Research Center Protéines de liaison spécifiques pour des néo-antigènes ras et leurs utilisations
WO2020185796A1 (fr) 2019-03-11 2020-09-17 Fred Hutchinson Cancer Research Center Récepteurs de lymphocytes t wt1 à haute avidité et leurs utilisations
WO2021034976A1 (fr) 2019-08-20 2021-02-25 Fred Hutchinson Cancer Research Center Immunothérapie par lymphocytes t, spécifique de wt-1
US11034748B2 (en) 2017-03-15 2021-06-15 Fred Hutchinson Cancer Research Center High affinity MAGE-A1-specific TCRs and uses thereof
EP3929279A1 (fr) 2014-03-18 2021-12-29 Sangamo Therapeutics, Inc. Procédés et compositions de régulation de l'expression de protéines en doigt de zinc
US11235026B2 (en) 2007-09-27 2022-02-01 Sangamo Therapeutics, Inc. Methods and compositions for modulating PD1
WO2022046760A2 (fr) 2020-08-25 2022-03-03 Kite Pharma, Inc. Lymphocytes t à fonctionnalité améliorée
WO2022066965A2 (fr) 2020-09-24 2022-03-31 Fred Hutchinson Cancer Research Center Immunothérapie ciblant des antigènes sox2
WO2022066973A1 (fr) 2020-09-24 2022-03-31 Fred Hutchinson Cancer Research Center Immunothérapie ciblant les antigènes pbk ou oip5
WO2022076353A1 (fr) 2020-10-06 2022-04-14 Fred Hutchinson Cancer Research Center Compositions et procédés de traitement de la maladie associée à l'expression de mage-a1
WO2022132836A2 (fr) 2020-12-14 2022-06-23 Fred Hutchinson Cancer Research Center Compositions et méthodes pour l'immunothérapie cellulaire
US11453639B2 (en) 2019-01-11 2022-09-27 Acuitas Therapeutics, Inc. Lipids for lipid nanoparticle delivery of active agents
WO2023288281A2 (fr) 2021-07-15 2023-01-19 Fred Hutchinson Cancer Center Polypeptides chimériques
WO2023014922A1 (fr) 2021-08-04 2023-02-09 The Regents Of The University Of Colorado, A Body Corporate Cellules t de récepteur d'antigène chimérique activant le lat et leurs méthodes d'utilisation
WO2023081756A1 (fr) 2021-11-03 2023-05-11 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Édition précise du génome à l'aide de rétrons
US11690921B2 (en) 2018-05-18 2023-07-04 Sangamo Therapeutics, Inc. Delivery of target specific nucleases
WO2023141602A2 (fr) 2022-01-21 2023-07-27 Renagade Therapeutics Management Inc. Rétrons modifiés et méthodes d'utilisation
EP4234570A2 (fr) 2018-09-18 2023-08-30 Sangamo Therapeutics, Inc. Nucléases spécifiques de la mort cellulaire programmée 1 (pd1)
WO2023215725A1 (fr) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions et méthodes pour l'immunothérapie cellulaire
US11820728B2 (en) 2017-04-28 2023-11-21 Acuitas Therapeutics, Inc. Carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
US11827904B2 (en) 2015-04-29 2023-11-28 Fred Hutchinson Cancer Center Modified stem cells and uses thereof
WO2024044723A1 (fr) 2022-08-25 2024-02-29 Renagade Therapeutics Management Inc. Rétrons modifiés et méthodes d'utilisation
US11976019B2 (en) 2020-07-16 2024-05-07 Acuitas Therapeutics, Inc. Cationic lipids for use in lipid nanoparticles
US11993652B2 (en) 2013-12-20 2024-05-28 Fred Hutchinson Cancer Center Tagged chimeric effector molecules and receptors thereof
US12129223B2 (en) 2021-12-16 2024-10-29 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
WO2025054540A1 (fr) 2023-09-08 2025-03-13 Iovance Biotherapeutics, Inc. Procédés d'édition génique à l'aide de nucléases programmables
WO2025081123A1 (fr) 2023-10-12 2025-04-17 Fred Hutchinson Cancer Center Procédés et compositions pour améliorer l'immunothérapie des lymphocytes t
WO2025101820A1 (fr) 2023-11-08 2025-05-15 Fred Hutchinson Cancer Center Compositions et méthodes pour l'immunothérapie cellulaire
US12329857B2 (en) 2018-09-21 2025-06-17 Acuitas Therapeutics, Inc. Systems and methods for manufacturing lipid nanoparticles and liposomes
WO2025245169A1 (fr) 2024-05-21 2025-11-27 Fred Hutchinson Cancer Center Cellules d'immunothérapie dotées d'une charge utile ciblant le collagène

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100151556A1 (en) * 2002-03-15 2010-06-17 Cellectis Hybrid and single chain meganucleases and use thereof
WO2009095742A1 (fr) 2008-01-31 2009-08-06 Cellectis Nouvelle méganucléase à chaîne unique dérivée de l'i-crei et ses utilisations
ATE372379T1 (de) 2002-03-15 2007-09-15 Cellectis Hybride and einzelkettige meganukleasen und deren anwendungen
US20060206949A1 (en) * 2003-01-28 2006-09-14 Sylvain Arnould Custom-made meganuclease and use thereof
EP1591521A1 (fr) * 2004-04-30 2005-11-02 Cellectis Dérivés de I-Dmo I ayant une activité améliorée à 37degrés C et leur utilisation
WO2007034262A1 (fr) * 2005-09-19 2007-03-29 Cellectis Méganucléases hétérodimériques et leur utilisation
WO2007014275A2 (fr) 2005-07-26 2007-02-01 Sangamo Biosciences, Inc. Integration et expression ciblees de sequences d'acides nucleiques exogenes
WO2007049095A1 (fr) 2005-10-25 2007-05-03 Cellectis Variants d'endonuclease de liaison a laglidadg comprenant des mutations dans deux sous-domaines fonctionnels et leur utilisation
WO2007060495A1 (fr) 2005-10-25 2007-05-31 Cellectis Variants de l'endonuclease homing i-crei a nouvelle specificite de clivage et leur utilisation
WO2008010009A1 (fr) * 2006-07-18 2008-01-24 Cellectis Variants de méganucléase clivant une séquence d'adn cible provenant d'un gène rag et leurs utilisations
WO2008093152A1 (fr) * 2007-02-01 2008-08-07 Cellectis Meganucleases heterodimeres obligatoires et leurs utilisations
AU2008263502A1 (en) 2007-06-06 2008-12-18 Cellectis Method for enhancing the cleavage activity of I-Crei derived meganucleases
WO2008149176A1 (fr) * 2007-06-06 2008-12-11 Cellectis Variants de méganucléase clivant une séquence cible d'adn issue du locus rosa26 de souris et leurs utilisations
EP2568048A1 (fr) 2007-06-29 2013-03-13 Pioneer Hi-Bred International, Inc. Procédés de modification du génome d'une cellule de plante monocotylédone
WO2009013559A1 (fr) 2007-07-23 2009-01-29 Cellectis Variants de méganucléase clivant une séquence cible d'adn à partir du gène bêta de l'hémoglobine humaine et ses utilisations
AU2015201270B2 (en) * 2007-10-31 2017-01-19 Precision Biosciences, Inc. Rationally-designed single-chain meganucleases with non-palindromic recognition sequences
EP2208785A1 (fr) 2009-01-15 2010-07-21 Newbiotechnic, S.A. Procédés et kits pour générer des vecteurs d'expression d'ARNm et petit ARN et leurs applications pour le développement de bibliothèques d'expression de lentivirus
WO2010122367A2 (fr) * 2009-04-21 2010-10-28 Cellectis Variants de méganucléases coupant l'insertion génomique d'un virus et applications associées
WO2010136981A2 (fr) 2009-05-26 2010-12-02 Cellectis Variants de méganucléase clivant le génome d'un virus non intégratif pathogène et leurs utilisations
WO2011007193A1 (fr) 2009-07-17 2011-01-20 Cellectis Vecteurs viraux codant pour une matrice de réparation d'adn et contenant une méganucléase spécifique de site associée à un virion pour un ciblage de gène
WO2011021062A1 (fr) 2009-08-21 2011-02-24 Cellectis Variants de méganucléase clivant une séquence d’adn cible du gène d’acide lysosomique alpha-glucosidase humain et utilisations de ceux-ci
CA2781835A1 (fr) 2009-11-27 2011-06-03 Basf Plant Science Company Gmbh Endonucleases chimeriques et utilisations de celles-ci
CN102686726B (zh) 2009-11-27 2015-12-16 巴斯夫植物科学有限公司 嵌合内切核酸酶及其用途
WO2011082310A2 (fr) 2009-12-30 2011-07-07 Pioneer Hi-Bred International, Inc. Procédés et compositions pour la modification ciblée de polynucléotides
US20130071373A1 (en) * 2010-02-02 2013-03-21 Christina Zeitz Methods for the diagnosis and therapy of retinitis pigmentosa
WO2011101696A1 (fr) 2010-02-18 2011-08-25 Cellectis Système de recombinaison de méganucléase amélioré
JP2013520190A (ja) * 2010-02-26 2013-06-06 セレクティス セーフハーバー遺伝子座への導入遺伝子の挿入のためのエンドヌクレアーゼの使用
EP2550358A1 (fr) 2010-03-22 2013-01-30 Philip Morris Products S.A. Modification d'activité enzymatique dans des plantes
US20130183282A1 (en) 2010-05-12 2013-07-18 Cellectis Meganuclease variants cleaving a DNA target sequence from the rhodopsin gene and uses thereof
CA2799095A1 (fr) 2010-05-12 2011-11-17 Cellectis Variants de meganuclease clivant une sequence cible d'adn du gene de dystrophine et leurs utilisations
CA2802822A1 (fr) 2010-06-15 2012-01-05 Cellectis Procede permettant d'ameliorer le clivage d'un adn par une endonuclease sensible a la methylation
WO2012004671A2 (fr) 2010-07-07 2012-01-12 Cellectis Variants de méganucléases coupant une séquence cible d'adn dans le gène nanog et leurs utilisations
WO2012010976A2 (fr) 2010-07-15 2012-01-26 Cellectis Variants de méganucléases clivant une séquence d'adn cible dans le gène tert et leurs utilisations
WO2012007848A2 (fr) 2010-07-16 2012-01-19 Cellectis Variants de méganucléase clivant une séquence d'adn cible dans le gène was et leurs utilisations
CA2807270A1 (fr) 2010-08-02 2012-02-09 Cellectis Procede destine a des evenements genomiques cibles dans des diatomees
EP2633040B1 (fr) 2010-10-27 2019-07-10 Cellectis Procédé permettant d'augmenter l'efficacité d'une mutagenèse induite par des cassures double brin
BR112013024337A2 (pt) 2011-03-23 2017-09-26 Du Pont locus de traço transgênico complexo em uma planta, planta ou semente, método para produzir em uma planta um locus de traço transgênico complexo e construto de expressão
SG194115A1 (en) 2011-04-05 2013-11-29 Cellectis Method for the generation of compact tale-nucleases and uses thereof
WO2012138901A1 (fr) 2011-04-05 2012-10-11 Cellectis Sa Procédé pour l'amélioration de l'efficacité d'endonucléases à coupure rare et ses utilisations
BR112013025567B1 (pt) 2011-04-27 2021-09-21 Amyris, Inc Métodos para modificação genômica
WO2012158778A1 (fr) 2011-05-16 2012-11-22 Cellectis S.A. Souches d'algues ou de cyanobactéries transgéniques deux fois plus sûres pour empêcher leur implantation et leur dissémination dans des écosystèmes naturels
WO2012168910A1 (fr) 2011-06-10 2012-12-13 Basf Plant Science Company Gmbh Protéine de fusion de nucléase et ses utilisations
BR112013033176A2 (pt) 2011-06-21 2018-06-12 E I Du Pont De Nemouras And Company método para produzir uma modificação direcionada em um gene de fertilidade masculina, planta, molécula de ácido nucleio isolada, construto de expressão
EP2729567B1 (fr) 2011-07-08 2016-10-05 Cellectis Procédé d'amélioration de l'efficacité de mutagenèse induite par une cassure double brin
CA2844101A1 (fr) 2011-08-03 2013-02-07 E. I. Du Pont De Nemours And Company Procedes et compositions permettant une integration ciblee dans une plante
US20150184173A1 (en) 2012-05-04 2015-07-02 E I Du Pont De Nemours And Company Compositions and methods comprising sequences having meganuclease activity
WO2014018601A2 (fr) 2012-07-24 2014-01-30 Cellectis Nouveaux domaines de liaison d'acide nucléique spécifiques à la base modulaires à partir de protéines burkholderia rhizoxinica
EP2920310A2 (fr) 2012-11-16 2015-09-23 Total Marketing Services Procédé pour la modification ciblée de génomes d'algue
WO2014102688A1 (fr) 2012-12-27 2014-07-03 Cellectis Nouvelle matrice de conception pour l'amélioration du ciblage génique dirigé par homologie
AU2014218931C1 (en) 2013-02-20 2020-05-14 Regeneron Pharmaceuticals, Inc. Genetic modification of rats
WO2014164466A1 (fr) 2013-03-12 2014-10-09 E. I. Du Pont De Nemours And Company Procédés d'identification de sites de reconnaissance de variant pour agents d'induction de cassure double brin à coupure rare, génétiquement modifiés, leurs compositions et leurs utilisations
KR102391734B1 (ko) * 2013-03-15 2022-04-29 인3바이오 리미티드 자기조립형 합성 단백질
HRP20181648T1 (hr) 2013-04-16 2019-01-25 Regeneron Pharmaceuticals, Inc. Ciljana modifikacija genoma štakora
RS58159B1 (sr) 2013-12-11 2019-03-29 Regeneron Pharma Postupci i kompozicije za ciljanu modifikaciju genoma
MX388127B (es) 2013-12-11 2025-03-19 Regeneron Pharma Metodos y composiciones para la modificacion dirigida de un genoma.
AU2014368982B2 (en) 2013-12-19 2021-03-25 Amyris, Inc. Methods for genomic integration
CA2950173C (fr) 2014-06-06 2023-10-10 Regeneron Pharmaceuticals, Inc. Procedes et compositions pour la modification d'un locus cible
ES2781323T3 (es) 2014-06-23 2020-09-01 Regeneron Pharma Montaje de ADN mediado por nucleasas
KR102386101B1 (ko) 2014-06-26 2022-04-14 리제너론 파마슈티칼스 인코포레이티드 표적화된 유전자 변형을 위한 방법 및 그 조성물, 및 사용 방법
PL3207124T3 (pl) 2014-10-15 2019-11-29 Regeneron Pharma Sposoby i kompozycje do wytwarzania lub utrzymywania komórek pluripotencjalnych
CN107208113A (zh) 2014-12-19 2017-09-26 瑞泽恩制药公司 用于通过单步多重靶向进行靶向遗传修饰的方法和组合物
JP7093310B2 (ja) 2016-05-18 2022-06-29 アミリス， インコーポレイテッド 外因性ランディングパッドへの核酸のゲノム組込みのための組成物および方法
MX2019001211A (es) 2016-07-29 2019-09-16 Regeneron Pharma Ratones que comprenden mutaciones que dan lugar a la expresión de la fibrilina-1 truncada en c.
CA3050715A1 (fr) 2017-01-19 2018-07-26 Open Monoclonal Technology, Inc. Anticorps humains provenant de rongeurs transgeniques ayant de multiples loci d'immunoglobuline a chaine lourde
AU2018325363B2 (en) 2017-08-29 2025-01-23 Global Crop Innovations Pty. Ltd. Improved BLue Aleurone and other segregation systems
EP3585162B1 (fr) 2017-09-29 2023-08-30 Regeneron Pharmaceuticals, Inc. Rongeurs comprenant un locus ttr humanisé et procédés d'utilisation
WO2019177976A1 (fr) 2018-03-12 2019-09-19 Pioneer Hi-Bred International, Inc. Procédés de transformation de plantes
KR20200071198A (ko) 2018-12-10 2020-06-19 네오이뮨텍, 인코퍼레이티드 Nrf2 발현 조절 기반 T 세포 항암면역치료법
AU2019403015B2 (en) 2018-12-20 2024-01-18 Regeneron Pharmaceuticals, Inc. Nuclease-mediated repeat expansion
ES2966625T3 (es) 2019-04-04 2024-04-23 Regeneron Pharma Roedores que comprenden un locus del factor de coagulación 12 humanizado
AU2020253531C1 (en) 2019-04-04 2022-06-16 Regeneron Pharmaceuticals, Inc. Methods for scarless introduction of targeted modifications into targeting vectors
JP7610339B2 (ja) 2019-06-04 2025-01-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ベータスリップ変異を有するヒト化ｔｔｒ遺伝子座を含む非ヒト動物と使用方法
CA3137764A1 (fr) 2019-06-07 2020-12-10 Regeneron Pharmaceuticals, Inc. Animaux non humains comprenant un locus d'albumine humanise
WO2021108363A1 (fr) 2019-11-25 2021-06-03 Regeneron Pharmaceuticals, Inc. Régulation à la hausse médiée par crispr/cas d'un allèle ttr humanisé
EP4337769A1 (fr) 2021-05-10 2024-03-20 SQZ Biotechnologies Company Méthodes pour administrer des molécules d'édition génomique au noyau ou au cytosol d'une cellule et leurs utilisations
WO2022251644A1 (fr) 2021-05-28 2022-12-01 Lyell Immunopharma, Inc. Cellules immunitaires déficientes en nr4a3 et leurs utilisations
EP4347826A1 (fr) 2021-06-02 2024-04-10 Lyell Immunopharma, Inc. Cellules immunitaires déficientes en nr4a3 et leurs utilisations
KR20240082391A (ko) 2021-10-14 2024-06-10 론자 세일즈 아게 세포외 소포 생산을 위한 변형된 생산자 세포
JP2025501221A (ja) 2021-12-29 2025-01-17 ブリストル－マイヤーズ スクイブ カンパニー ランディングパッド細胞株の生成
CA3256953A1 (fr) 2022-05-09 2023-11-16 Regeneron Pharmaceuticals, Inc. Vecteurs et procédés de production d'anticorps in vivo
JP2025516823A (ja) 2022-05-19 2025-05-30 ライエル・イミュノファーマ・インコーポレイテッド Ｎｒ４ａ３を標的とするポリヌクレオチド及びその使用
WO2024064958A1 (fr) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Procédés de culture de cellules déficientes en nr4a
WO2024064952A1 (fr) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Procédés de culture de cellules déficientes en nr4a surexprimant c-jun

Citations (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US5006333A (en) * 1987-08-03 1991-04-09 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5272071A (en) * 1989-12-22 1993-12-21 Applied Research Systems Ars Holding N.V. Method for the modification of the expression characteristics of an endogenous gene of a given cell line
US5436150A (en) * 1992-04-03 1995-07-25 The Johns Hopkins University Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease
US5474896A (en) * 1992-05-05 1995-12-12 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
US5641670A (en) * 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5792632A (en) * 1992-05-05 1998-08-11 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
US5801030A (en) * 1995-09-01 1998-09-01 Genvec, Inc. Methods and vectors for site-specific recombination
US5830729A (en) * 1996-04-18 1998-11-03 Institut Pasteur I Sce I-induced gene replacement and gene conversion in embryonic stem cells
US5843701A (en) * 1990-08-02 1998-12-01 Nexstar Pharmaceticals, Inc. Systematic polypeptide evolution by reverse translation
US6037162A (en) * 1997-02-17 2000-03-14 Ben Gurion University DNA segments encoding a domain of HO-endonuclease
US6063630A (en) * 1991-11-05 2000-05-16 Transkaryotic Therapies, Inc. Targeted introduction of DNA into primary or secondary cells and their use for gene therapy
US6232112B1 (en) * 1997-11-24 2001-05-15 Flinders Technologies Pty Ltd Of Flinders University Reagents and methods for diversification of DNA
US6395959B1 (en) * 1992-05-05 2002-05-28 Institut Pasteur Nucleotide sequence encoding the enzyme I SceI and the use thereof
US6528314B1 (en) * 1989-03-20 2003-03-04 Institut Pasteur Procedure for specific replacement of a copy of a gene present in the recipient genome by the integration of a gene different from that where the integration is made
US20030096249A1 (en) * 2000-12-21 2003-05-22 Westphal Ryan S. Nucleic acid molecules and polypeptides for a human cation channel polypeptide
US20030228583A1 (en) * 2001-10-31 2003-12-11 Amacher David E. Biomarkers of liver response
US20040002092A1 (en) * 2002-03-15 2004-01-01 Sylvain Arnould Hybrid and single chain meganucleases and use thereof
US20040019916A1 (en) * 1992-04-24 2004-01-29 Zarling David A. In vivo homologous sequence targeting in eukaryotic cells
US20050064474A1 (en) * 2003-08-08 2005-03-24 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US20050172365A1 (en) * 2001-07-04 2005-08-04 Holger Puchta Recombination systems and methods for eliminating nucleic acid sequences from the genome of eukaryotic organisms
US20060206949A1 (en) * 2003-01-28 2006-09-14 Sylvain Arnould Custom-made meganuclease and use thereof
US7462758B2 (en) * 2001-12-20 2008-12-09 Sungene Gmbh & Co. Kgaa Methods for the transformation of vegetal plastids

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994018313A1 (fr) 1993-02-12 1994-08-18 The Johns-Hopkins University Domaines fonctionnels dans l'endonuclease de restriction d'okeanokoites flavobacterium
JP2002535994A (ja) 1999-02-03 2002-10-29 ザ チルドレンズ メディカル センター コーポレイション 標的ｄｎａのインビボ除去による遺伝子修復
JP2002535995A (ja) 1999-02-03 2002-10-29 ザ チルドレンズ メディカル センター コーポレイション 染色体標的部位での二本鎖ｄｎａ切断の誘導を含む遺伝子修復
WO2009095742A1 (fr) † 2008-01-31 2009-08-06 Cellectis Nouvelle méganucléase à chaîne unique dérivée de l'i-crei et ses utilisations
EP1591521A1 (fr) † 2004-04-30 2005-11-02 Cellectis Dérivés de I-Dmo I ayant une activité améliorée à 37degrés C et leur utilisation
ES2539616T3 (es) † 2005-10-18 2015-07-02 Precision Biosciences Meganucleasa diseñada racionalmente con afinidad de formación de dímeros alterada
EP2568048A1 (fr) † 2007-06-29 2013-03-13 Pioneer Hi-Bred International, Inc. Procédés de modification du génome d'une cellule de plante monocotylédone
AU2008318430A1 (en) † 2007-10-31 2009-05-07 Precision Biosciences, Inc. Rationally-designed single-chain meganucleases with non-palindromic recognition sequences
WO2009074842A1 (fr) † 2007-12-13 2009-06-18 Cellectis Enzymes chimères améliorées de méganucléase et leurs utilisations

Patent Citations (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US5006333A (en) * 1987-08-03 1991-04-09 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US20040203153A1 (en) * 1989-03-20 2004-10-14 Institut Pasteur Procedure for specific replacement of a copy of a gene present in the recipient genome by the integration of a gene different from that where the integration is made
US6528313B1 (en) * 1989-03-20 2003-03-04 Institut Pasteur Procedure for specific replacement of a copy of a gene present in the recipient genome by the integration of a gene different from that where the integration is made
US6528314B1 (en) * 1989-03-20 2003-03-04 Institut Pasteur Procedure for specific replacement of a copy of a gene present in the recipient genome by the integration of a gene different from that where the integration is made
US5272071A (en) * 1989-12-22 1993-12-21 Applied Research Systems Ars Holding N.V. Method for the modification of the expression characteristics of an endogenous gene of a given cell line
US5843701A (en) * 1990-08-02 1998-12-01 Nexstar Pharmaceticals, Inc. Systematic polypeptide evolution by reverse translation
US6063630A (en) * 1991-11-05 2000-05-16 Transkaryotic Therapies, Inc. Targeted introduction of DNA into primary or secondary cells and their use for gene therapy
US5641670A (en) * 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5436150A (en) * 1992-04-03 1995-07-25 The Johns Hopkins University Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease
US20040019916A1 (en) * 1992-04-24 2004-01-29 Zarling David A. In vivo homologous sequence targeting in eukaryotic cells
US5866361A (en) * 1992-05-05 1999-02-02 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
US5962327A (en) * 1992-05-05 1999-10-05 Institut Pasteur Universite Paris-Vi Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
US7309605B1 (en) * 1992-05-05 2007-12-18 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
US5948678A (en) * 1992-05-05 1999-09-07 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
US6833252B1 (en) * 1992-05-05 2004-12-21 Institut Pasteur Nucleotide sequence encoding the enzyme I-SecI and the uses thereof
US6238924B1 (en) * 1992-05-05 2001-05-29 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
US6395959B1 (en) * 1992-05-05 2002-05-28 Institut Pasteur Nucleotide sequence encoding the enzyme I SceI and the use thereof
US5792632A (en) * 1992-05-05 1998-08-11 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
US6822137B1 (en) * 1992-05-05 2004-11-23 Institut Pasteur Nucleotide sequence encoding the enzyme I-SCEI and the uses thereof
US5474896A (en) * 1992-05-05 1995-12-12 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
US6610545B2 (en) * 1992-05-05 2003-08-26 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
US5801030A (en) * 1995-09-01 1998-09-01 Genvec, Inc. Methods and vectors for site-specific recombination
US5830729A (en) * 1996-04-18 1998-11-03 Institut Pasteur I Sce I-induced gene replacement and gene conversion in embryonic stem cells
US6566579B1 (en) * 1996-04-18 2003-05-20 Institut Pasteur I-Sce I induced gene replacement and gene conversion in embryonic stem cells
US6037162A (en) * 1997-02-17 2000-03-14 Ben Gurion University DNA segments encoding a domain of HO-endonuclease
US6232112B1 (en) * 1997-11-24 2001-05-15 Flinders Technologies Pty Ltd Of Flinders University Reagents and methods for diversification of DNA
US20030096249A1 (en) * 2000-12-21 2003-05-22 Westphal Ryan S. Nucleic acid molecules and polypeptides for a human cation channel polypeptide
US20050172365A1 (en) * 2001-07-04 2005-08-04 Holger Puchta Recombination systems and methods for eliminating nucleic acid sequences from the genome of eukaryotic organisms
US20030228583A1 (en) * 2001-10-31 2003-12-11 Amacher David E. Biomarkers of liver response
US7462758B2 (en) * 2001-12-20 2008-12-09 Sungene Gmbh & Co. Kgaa Methods for the transformation of vegetal plastids
US20040002092A1 (en) * 2002-03-15 2004-01-01 Sylvain Arnould Hybrid and single chain meganucleases and use thereof
US20060206949A1 (en) * 2003-01-28 2006-09-14 Sylvain Arnould Custom-made meganuclease and use thereof
US20050064474A1 (en) * 2003-08-08 2005-03-24 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination

Cited By (155)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100021448A1 (en) * 2005-03-15 2010-01-28 Cellectis I-crei meganuclease variants with modified specificity, method of preparation and uses thereof
US7897372B2 (en) 2005-03-15 2011-03-01 Cellectis I-CreI meganuclease variants with modified specificity, method of preparation and uses thereof
US8715992B2 (en) 2005-03-15 2014-05-06 Cellectis I-CreI meganuclease variants with modified specificity, method of preparation and uses thereof
US8163514B2 (en) 2005-10-18 2012-04-24 Duke University Methods of cleaving DNA with rationally-designed meganucleases
EP2327774A2 (fr) 2005-10-18 2011-06-01 Precision Biosciences Méganucléases conçues rationnellement possédant une spécificité de séquence modifiée et une affinité de liaison modifiée pour L'ADN
EP3795682A2 (fr) 2005-10-18 2021-03-24 Precision Biosciences Meganucleases concues rationnellement possedant une specificité sequence modifiée et une affinité de liaison pour l'adn
EP2662442A1 (fr) 2005-10-18 2013-11-13 Precision Biosciences Meganucléases conçues rationnellement possédant une specificité séquence modifiée et une affinité de liaison pour l'ADN
EP2650365A1 (fr) 2005-10-18 2013-10-16 Precision Biosciences Meganucleases concues rationnellement possedant une specificité sequence modifiée et une affinité de liaison pour l'ADN
EP2628794A2 (fr) 2005-10-18 2013-08-21 Precision Biosciences Méganucléases concues rationnellement possedant une specificité de séquence modifiée et une affinité de liaison pour l'ADN
US8119381B2 (en) 2005-10-18 2012-02-21 Duke University Rationally-designed meganucleases with altered sequence specificity and DNA-binding affinity
US8377674B2 (en) 2005-10-18 2013-02-19 Duke University Method for producing genetically-modified cells with rationally-designed meganucleases with altered sequence specificity
US8304222B1 (en) 2005-10-18 2012-11-06 Duke University Rationally-designed meganucleases with altered sequence specificity and heterodimer formation
EP2484758A1 (fr) 2005-10-18 2012-08-08 Precision Biosciences Meganucleases concues rationnellement possedant une specificite sequence modifiee et une affinite de liaison pour l'ADN
EP2368981A2 (fr) 2005-10-18 2011-09-28 Precision Biosciences Méganucléases conçues rationnellement possédant une spécificité de séquence modifiée et une affinité de liaison modifiée pour L'ADN
US8119361B2 (en) 2005-10-18 2012-02-21 Duke University Methods of cleaving DNA with rationally-designed meganucleases
US8148098B2 (en) 2005-10-18 2012-04-03 Duke University Methods of cleaving DNA with rationally-designed meganucleases
EP3246403A2 (fr) 2005-10-18 2017-11-22 Precision Biosciences Meganucleases concues rationnellement possedant une specificité sequence modifiée et une affinité de liaison pour l'adn
US8143016B2 (en) 2005-10-18 2012-03-27 Duke University Methods of cleaving DNA with rationally-designed meganucleases
US8021867B2 (en) 2005-10-18 2011-09-20 Duke University Rationally-designed meganucleases with altered sequence specificity and DNA-binding affinity
EP2341135A2 (fr) 2005-10-18 2011-07-06 Precision Biosciences Méganucléases conçues rationnellement possédant une spécificité de séquence modifiée et une affinité de liaison modifiée pour L'ADN
US8143015B2 (en) 2005-10-18 2012-03-27 Duke University Methods of cleaving DNA with rationally-designed meganucleases
EP2357226A1 (fr) 2005-10-18 2011-08-17 Precision Biosciences Méganucléases conçues rationnellement possédant une spécificité de séquence modifiée et une affinité de liaison modifiée pour L'ADN
US8133697B2 (en) 2005-10-18 2012-03-13 Duke University Methods of cleaving DNA with rationally-designed meganucleases
EP2360244A1 (fr) 2005-10-18 2011-08-24 Precision Biosciences Méganucléases conçues rationnellement possédant une spécificité de séquence modifiée et une affinité de liaison modifiée pour L'ADN
US8129134B2 (en) 2005-10-18 2012-03-06 Duke University Methods of cleaving DNA with rationally-designed meganucleases
US8124369B2 (en) 2005-10-18 2012-02-28 Duke University Method of cleaving DNA with rationally-designed meganucleases
EP2336329A1 (fr) 2007-06-01 2011-06-22 Omt, Inc. Compositions et procédés pour inhiber des gênes d' immunoglobuline endogènes et produire des anticorps d'idiotype humain transgéniques
EP3382022A1 (fr) 2007-06-01 2018-10-03 Open Monoclonal Technology, Inc. Compositions et procedes pour inhiber des genes d'immunoglobuline endogenes et produire des anticorps d'idiotype humains transgeniques
EP2602323A1 (fr) 2007-06-01 2013-06-12 Omt, Inc. Compositions et procédé pour inhiber des gènes de lýimmunoglobine endogène et produire des anticorps dýidiotype humain transgéniques
US20110207199A1 (en) * 2007-08-03 2011-08-25 Cellectis Novel method to generate meganucleases with altered characteristics
US9402879B2 (en) 2007-09-27 2016-08-02 Sangamo Biosciences, Inc. Methods and compositions for modulating PD1
US9121072B2 (en) 2007-09-27 2015-09-01 Sangamo Biosciences, Inc. Rapid screening of biologically active nucleases and isolation of nuclease-modified cells
WO2009042163A3 (fr) * 2007-09-27 2009-05-22 Sangamo Biosciences Inc Identification in vivo rapide de nucléases biologiquement actives
AU2008305567B2 (en) * 2007-09-27 2014-04-10 Sangamo Therapeutics, Inc. Rapid in vivo identification of biologically active nucleases
US10046028B2 (en) 2007-09-27 2018-08-14 Sangamo Therapeutics, Inc. Methods and compositions for modulating PD1
US9115409B2 (en) 2007-09-27 2015-08-25 Sangamo Biosciences, Inc. Rapid screening of biologically active nucleases and isolation of nuclease-modified cells
US20090111119A1 (en) * 2007-09-27 2009-04-30 Yannick Doyon Rapid in vivo identification of biologically active nucleases
US11235026B2 (en) 2007-09-27 2022-02-01 Sangamo Therapeutics, Inc. Methods and compositions for modulating PD1
US8563314B2 (en) 2007-09-27 2013-10-22 Sangamo Biosciences, Inc. Methods and compositions for modulating PD1
US9506120B2 (en) 2007-09-27 2016-11-29 Sangamo Biosciences, Inc. Rapid in vivo identification of biologically active nucleases
US10041053B2 (en) 2007-10-31 2018-08-07 Precision Biosciences, Inc. Rationally-designed single-chain meganucleases with non-palindromic recognition sequences
US8445251B2 (en) 2007-10-31 2013-05-21 Precision Biosciences, Inc. Rationally-designed single-chain meganucleases with non-palindromic recognition sequences
EP2215223A4 (fr) * 2007-10-31 2011-01-05 Prec Biosciences Inc Méganucléases monocaténaires conçues rationnellement contenant des séquences de reconnaissance non palindromiques
US20100311817A1 (en) * 2007-10-31 2010-12-09 Smith James J Rationally-designed single-chain meganucleases with non-palindromic recognition sequences
US9434931B2 (en) 2007-10-31 2016-09-06 Precision Biosciences, Inc. Rationally-designed single-chain meganucleases with non-palindromic recognition sequences
US12351839B2 (en) 2007-10-31 2025-07-08 Precision Biosciences, Inc. Rationally-designed single-chain meganucleases with non-palindromic recognition sequences
US9340777B2 (en) 2007-10-31 2016-05-17 Precision Biosciences, Inc. Rationally-designed single-chain meganucleases with non-palindromic recognition sequences
EP3578646A3 (fr) * 2007-10-31 2020-03-18 Precision Biosciences, Inc. Méganucléases monocaténaires concues rationnellement contenant des séquences de reconnaissance non palindromiques
US20110033935A1 (en) * 2007-12-07 2011-02-10 Precision Biosciences, Inc. Rationally-designed meganucleases with recognition sequences found in dnase hypersensitive regions of the human genome
US20110173710A1 (en) * 2007-12-13 2011-07-14 Cellectis Chimeric meganuclease enzymes and uses thereof
WO2009114321A3 (fr) * 2008-03-11 2010-02-04 Precision Biosciences, Inc. Méganucléases rationnellement conçues pour modification par génie génétique du génome du maïs
US20110113509A1 (en) * 2008-03-11 2011-05-12 Precision Biosciences, Inc. Rationally-designed meganucleases for maize genome engineering
US8338157B2 (en) 2008-03-11 2012-12-25 Precision Biosciences, Inc. Rationally-designed meganuclease variants of lig-34 and I-crei for maize genome engineering
US20100071083A1 (en) * 2008-03-12 2010-03-18 Smith James J Temperature-dependent meganuclease activity
WO2009134714A3 (fr) * 2008-04-28 2010-01-28 Precision Biosciences, Inc. Molécules de fusion de protéines de liaison à l'adn et de domaines effecteurs conçus de façon rationnelle
US20110123509A1 (en) * 2008-04-28 2011-05-26 Derek Jantz Fusion molecules of rationally-designed dna-binding proteins and effector domains
US20110202479A1 (en) * 2008-07-14 2011-08-18 Derek Jantz Recognition sequences for i-crei-derived meganucleases and uses thereof
US10273524B2 (en) 2008-07-14 2019-04-30 Precision Biosciences, Inc. Recognition sequences for I-CreI-derived meganucleases and uses thereof
US10287626B2 (en) 2008-07-14 2019-05-14 Precision Biosciences, Inc. Recognition sequences for I-CreI-derived meganucleases and uses thereof
US9683257B2 (en) 2008-07-14 2017-06-20 Precision Biosciences, Inc. Recognition sequences for I-CreI-derived meganucleases and uses thereof
US20110225664A1 (en) * 2008-09-08 2011-09-15 Cellectis Meganuclease variants cleaving a dna target sequence from a glutamine synthetase gene and uses thereof
US9273296B2 (en) 2008-09-08 2016-03-01 Cellectis Meganuclease variants cleaving a DNA target sequence from a glutamine synthetase gene and uses thereof
US9365864B2 (en) 2008-10-23 2016-06-14 Cellectis Meganuclease recombination system
WO2010093966A3 (fr) * 2009-02-12 2010-10-14 Fred Hutchinson Cancer Research Center Génération d'une enzyme de césure de l'adn stimulant la conversion d'un gène spécifique d'un site à partir d'une endonucléase de ciblage
WO2010107493A2 (fr) 2009-03-20 2010-09-23 Sangamo Biosciences, Inc. Modification de cxcr4 en utilisant des protéines à doigt de zinc modifiées
US20110129898A1 (en) * 2009-05-18 2011-06-02 Yannick Doyon Methods and compositions for increasing nuclease activity
US8772009B2 (en) 2009-05-18 2014-07-08 Sangamo Biosciences, Inc. Methods and compositions for increasing nuclease activity
US8772008B2 (en) 2009-05-18 2014-07-08 Sangamo Biosciences, Inc. Methods and compositions for increasing nuclease activity
US20110014616A1 (en) * 2009-06-30 2011-01-20 Sangamo Biosciences, Inc. Rapid screening of biologically active nucleases and isolation of nuclease-modified cells
AU2010266705B2 (en) * 2009-06-30 2014-06-05 Sangamo Therapeutics, Inc. Rapid screening of biologically active nucleases and isolation of nuclease-modified cells
EP2727600A1 (fr) 2009-07-28 2014-05-07 Sangamo BioSciences, Inc. Procédés et compositions pour le traitement de maladies à répétition trinucléotidique
EP3428289A1 (fr) 2009-08-11 2019-01-16 Sangamo Therapeutics, Inc. Organismes homozygotes destinés à une modification ciblée
EP3156504A1 (fr) 2009-08-11 2017-04-19 Sangamo BioSciences, Inc. Organismes homozygotes destinés à une modification ciblée
US20110041195A1 (en) * 2009-08-11 2011-02-17 Sangamo Biosciences, Inc. Organisms homozygous for targeted modification
US10827731B2 (en) 2009-08-11 2020-11-10 Sangamo Therapeutics, Inc. Method of inactivating the IPK1 gene in corn
US8802437B2 (en) 2009-09-24 2014-08-12 Cellectis Meganuclease reagents of uses thereof for treating genetic diseases caused by frame shift/non sense mutations
EP3156062A1 (fr) 2010-05-17 2017-04-19 Sangamo BioSciences, Inc. Nouvelles protéines à liaison adn et leurs utilisations
EP3311822A1 (fr) 2010-11-17 2018-04-25 Sangamo Therapeutics, Inc. Procédés et compositions pour la modulation de pd1
US9044492B2 (en) 2011-02-04 2015-06-02 Cellectis Sa Method for modulating the efficiency of double-strand break-induced mutagenesis
US10857203B2 (en) 2012-02-29 2020-12-08 Sangamo Therapeutics, Inc. Methods and compositions for treating Huntington's disease
US8841260B2 (en) 2012-02-29 2014-09-23 Sangamo Biosciences, Inc. Methods and compositions for treating Huntington's Disease
US11723952B2 (en) 2012-02-29 2023-08-15 Sangamo Therapeutics, Inc. Methods and compositions for treating Huntington's Disease
US10265377B2 (en) 2012-02-29 2019-04-23 Sangamo Therapeutics, Inc. Methods and compositions for treating Huntington's Disease
US10471123B2 (en) 2012-02-29 2019-11-12 Sangamo Therapeutics, Inc. Methods and compositions for treating Huntington's disease
WO2013130824A1 (fr) 2012-02-29 2013-09-06 Sangamo Biosciences, Inc. Procédés et compositions permettant de traiter la maladie de huntington
US9499597B2 (en) 2012-02-29 2016-11-22 Sangamo Biosciences, Inc. Methods and compositions for treating Huntington's disease
EP3763810A2 (fr) 2012-10-10 2021-01-13 Sangamo Therapeutics, Inc. Composés de modification de cellules t et leurs utilisations
WO2014059173A2 (fr) 2012-10-10 2014-04-17 Sangamo Biosciences, Inc. Composés modifiant les lymphocytes t et leurs utilisations
US9597357B2 (en) 2012-10-10 2017-03-21 Sangamo Biosciences, Inc. T cell modifying compounds and uses thereof
WO2015070212A1 (fr) 2013-11-11 2015-05-14 Sangamo Biosciences, Inc. Méthodes et compositions pour traiter la maladie de huntington
US10369201B2 (en) 2013-11-11 2019-08-06 Sangamo Therapeutics, Inc. Methods and compositions for treating Huntington's disease
US11993652B2 (en) 2013-12-20 2024-05-28 Fred Hutchinson Cancer Center Tagged chimeric effector molecules and receptors thereof
EP3929279A1 (fr) 2014-03-18 2021-12-29 Sangamo Therapeutics, Inc. Procédés et compositions de régulation de l'expression de protéines en doigt de zinc
EP4335918A2 (fr) 2015-04-03 2024-03-13 Dana-Farber Cancer Institute, Inc. Composition et procédés d'édition génomique de lymphocytes b
WO2017176806A1 (fr) 2015-04-03 2017-10-12 Dana-Farber Cancer Institute, Inc. Composition et méthodes d'édition génomique de lymphocytes b
WO2016161446A1 (fr) 2015-04-03 2016-10-06 Dana-Farber Cancer Institute, Inc. Composition et procédés de correction génomique de cellules b
EP4541900A2 (fr) 2015-04-03 2025-04-23 Dana-Farber Cancer Institute, Inc. Composition et méthodes d'édition génomique de lymphocytes b
US11827904B2 (en) 2015-04-29 2023-11-28 Fred Hutchinson Cancer Center Modified stem cells and uses thereof
WO2017106537A2 (fr) 2015-12-18 2017-06-22 Sangamo Biosciences, Inc. Disruption ciblée du récepteur des cellules du cmh
WO2017106528A2 (fr) 2015-12-18 2017-06-22 Sangamo Biosciences, Inc. Disruption ciblée du récepteur des lymphocytes t
EP3964573A1 (fr) 2016-08-24 2022-03-09 Sangamo Therapeutics, Inc. Nucléases spécifiques de cible spécifiquement modifiées
WO2018039448A1 (fr) 2016-08-24 2018-03-01 Sangamo Therapeutics, Inc. Nucléases spécifiques de cible spécifiquement modifiées
US10538574B2 (en) 2016-09-23 2020-01-21 Fred Hutchinson Cancer Research Center TCRS specific for minor histocompatibility (H) antigen HA-1 and uses thereof
WO2018058002A1 (fr) 2016-09-23 2018-03-29 Fred Hutchinson Cancer Research Center Tcr spécifiques de l'antigène ha-1 d'histocompatibilité (h) mineure et ses utilisations
US11034748B2 (en) 2017-03-15 2021-06-15 Fred Hutchinson Cancer Research Center High affinity MAGE-A1-specific TCRs and uses thereof
US11820728B2 (en) 2017-04-28 2023-11-21 Acuitas Therapeutics, Inc. Carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2018204469A2 (fr) 2017-05-03 2018-11-08 Sangamo Therapeutics, Inc. Méthodes et compositions pour la modification d'un gène régulateur de la conductance transmembranaire de la mucoviscidose (cftr)
US12043650B2 (en) 2017-05-03 2024-07-23 Sangamo Therapeutics, Inc. Methods and compositions for modification of a cystic fibrosis transmembrane conductance regulator (CFTR) gene
US11655275B2 (en) 2017-05-03 2023-05-23 Sangamo Therapeutics, Inc. Methods and compositions for modification of a cystic fibrosis transmembrane conductance regulator (CFTR) gene
US10780119B2 (en) 2017-05-24 2020-09-22 Effector Therapeutics Inc. Methods and compositions for cellular immunotherapy
WO2018218038A1 (fr) 2017-05-24 2018-11-29 Effector Therapeutics, Inc. Méthodes et compositions d'immunothérapie cellulaire
US11564947B2 (en) 2017-05-24 2023-01-31 Effector Therapeutics Inc. Methods and compositions for cellular immunotherapy
US12398191B2 (en) 2017-08-11 2025-08-26 Fred Hutchinson Cancer Center BRAF-specific TCRs and uses thereof
EP3665191A1 (fr) 2017-08-11 2020-06-17 Fred Hutchinson Cancer Research Center Tcr de braf spécifiques et utilisations associées
US12350312B2 (en) 2017-09-06 2025-07-08 Fred Hutchinson Cancer Center Methods for improving adoptive cell therapy
WO2019051128A1 (fr) 2017-09-06 2019-03-14 Fred Hutchinson Cancer Research Center Récepteurs chimériques spécifiques d'étiquette strep et utilisations de ceux-ci
WO2019051135A1 (fr) 2017-09-06 2019-03-14 Fred Hutchinson Cancer Research Center Méthodes pour améliorer une thérapie cellulaire adoptive
WO2019079777A1 (fr) 2017-10-20 2019-04-25 Fred Hutchinson Cancer Research Center Compositions et procédés d'immunothérapie ciblant tigit et/ou cd112r ou comprenant la surexpression de cd226
WO2019109047A1 (fr) 2017-12-01 2019-06-06 Fred Hutchinson Cancer Research Center Protéines de liaison spécifiques à 5t4 et leurs utilisations
WO2019140278A1 (fr) 2018-01-11 2019-07-18 Fred Hutchinson Cancer Research Center Immunothérapie ciblant des antigènes du facteur de liaison du noyau
WO2019165116A1 (fr) 2018-02-26 2019-08-29 Fred Hutchinson Cancer Research Center Compositions et méthodes pour immunothérapie cellulaire
US11690921B2 (en) 2018-05-18 2023-07-04 Sangamo Therapeutics, Inc. Delivery of target specific nucleases
WO2020018964A1 (fr) 2018-07-20 2020-01-23 Fred Hutchinson Cancer Research Center Compositions et procédés pour réguler l'expression de récepteurs spécifiques à l'antigène
WO2020041501A1 (fr) 2018-08-22 2020-02-27 Fred Hutchinson Cancer Research Center Immunothérapie ciblant les antigènes kras ou her2
WO2020047099A1 (fr) 2018-08-28 2020-03-05 Fred Hutchinson Cancer Research Center Procédés et compositions pour thérapie adoptive par lymphocytes t comportant une signalisation notch induite
EP4234570A2 (fr) 2018-09-18 2023-08-30 Sangamo Therapeutics, Inc. Nucléases spécifiques de la mort cellulaire programmée 1 (pd1)
US12329857B2 (en) 2018-09-21 2025-06-17 Acuitas Therapeutics, Inc. Systems and methods for manufacturing lipid nanoparticles and liposomes
WO2020068702A1 (fr) 2018-09-24 2020-04-02 Fred Hutchinson Cancer Research Center Protéines de récepteur chimérique et leurs utilisations
WO2020097530A2 (fr) 2018-11-09 2020-05-14 Fred Hutchinson Cancer Research Center Immunothérapie ciblant la mésothéline
US11453639B2 (en) 2019-01-11 2022-09-27 Acuitas Therapeutics, Inc. Lipids for lipid nanoparticle delivery of active agents
US11382954B2 (en) 2019-02-20 2022-07-12 Fred Hutchinson Cancer Center Binding proteins specific for RAS neoantigens and uses thereof
WO2020172332A1 (fr) 2019-02-20 2020-08-27 Fred Hutchinson Cancer Research Center Protéines de liaison spécifiques pour des néo-antigènes ras et leurs utilisations
US11458191B2 (en) 2019-02-20 2022-10-04 Fred Hutchinson Cancer Center Binding proteins specific for RAS neoantigens and uses thereof
US12448430B2 (en) 2019-03-11 2025-10-21 Fred Hutchinson Cancer Center High avidity WT1 T cell receptors and uses thereof
WO2020185796A1 (fr) 2019-03-11 2020-09-17 Fred Hutchinson Cancer Research Center Récepteurs de lymphocytes t wt1 à haute avidité et leurs utilisations
WO2021034976A1 (fr) 2019-08-20 2021-02-25 Fred Hutchinson Cancer Research Center Immunothérapie par lymphocytes t, spécifique de wt-1
US11976019B2 (en) 2020-07-16 2024-05-07 Acuitas Therapeutics, Inc. Cationic lipids for use in lipid nanoparticles
US12410121B2 (en) 2020-07-16 2025-09-09 Acuitas Therapeutics, Inc. Cationic lipids for use in lipid nanoparticles
EP4501951A2 (fr) 2020-08-25 2025-02-05 Kite Pharma, Inc. Lymphocytes t à fonctionnalité améliorée
WO2022046760A2 (fr) 2020-08-25 2022-03-03 Kite Pharma, Inc. Lymphocytes t à fonctionnalité améliorée
WO2022066973A1 (fr) 2020-09-24 2022-03-31 Fred Hutchinson Cancer Research Center Immunothérapie ciblant les antigènes pbk ou oip5
WO2022066965A2 (fr) 2020-09-24 2022-03-31 Fred Hutchinson Cancer Research Center Immunothérapie ciblant des antigènes sox2
WO2022076353A1 (fr) 2020-10-06 2022-04-14 Fred Hutchinson Cancer Research Center Compositions et procédés de traitement de la maladie associée à l'expression de mage-a1
WO2022132836A2 (fr) 2020-12-14 2022-06-23 Fred Hutchinson Cancer Research Center Compositions et méthodes pour l'immunothérapie cellulaire
WO2023288281A2 (fr) 2021-07-15 2023-01-19 Fred Hutchinson Cancer Center Polypeptides chimériques
WO2023014922A1 (fr) 2021-08-04 2023-02-09 The Regents Of The University Of Colorado, A Body Corporate Cellules t de récepteur d'antigène chimérique activant le lat et leurs méthodes d'utilisation
WO2023081756A1 (fr) 2021-11-03 2023-05-11 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Édition précise du génome à l'aide de rétrons
US12129223B2 (en) 2021-12-16 2024-10-29 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
WO2023141602A2 (fr) 2022-01-21 2023-07-27 Renagade Therapeutics Management Inc. Rétrons modifiés et méthodes d'utilisation
WO2023215725A1 (fr) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions et méthodes pour l'immunothérapie cellulaire
WO2024044723A1 (fr) 2022-08-25 2024-02-29 Renagade Therapeutics Management Inc. Rétrons modifiés et méthodes d'utilisation
WO2025054540A1 (fr) 2023-09-08 2025-03-13 Iovance Biotherapeutics, Inc. Procédés d'édition génique à l'aide de nucléases programmables
WO2025081123A1 (fr) 2023-10-12 2025-04-17 Fred Hutchinson Cancer Center Procédés et compositions pour améliorer l'immunothérapie des lymphocytes t
WO2025101820A1 (fr) 2023-11-08 2025-05-15 Fred Hutchinson Cancer Center Compositions et méthodes pour l'immunothérapie cellulaire
WO2025245169A1 (fr) 2024-05-21 2025-11-27 Fred Hutchinson Cancer Center Cellules d'immunothérapie dotées d'une charge utile ciblant le collagène

Also Published As

Publication number Publication date
ATE372379T1 (de) 2007-09-15
US8206965B2 (en) 2012-06-26
AU2003215869A1 (en) 2003-09-29
EP1485475B1 (fr) 2007-09-05
DE60316124D1 (de) 2007-10-18
ES2292994T3 (es) 2008-03-16
WO2003078619A1 (fr) 2003-09-25
CA2479153C (fr) 2015-06-02
US20040002092A1 (en) 2004-01-01
DE60316124T2 (de) 2008-06-05
JP2005520519A (ja) 2005-07-14
DE60316124T3 (de) 2018-03-22
EP1485475B2 (fr) 2017-09-20
DK1485475T3 (da) 2008-01-21
EP1485475A1 (fr) 2004-12-15
JP2010207234A (ja) 2010-09-24
CA2479153A1 (fr) 2003-09-25
JP2011188867A (ja) 2011-09-29
AU2003215869B2 (en) 2008-04-24

Similar Documents

Publication Publication Date Title
US8206965B2 (en) Hybrid and single chain meganucleases and use thereof
US20100151556A1 (en) Hybrid and single chain meganucleases and use thereof
US8927247B2 (en) I-CreI derived single-chain meganuclease and uses thereof
EP2121004B1 (fr) Méganucléases hétérodimères obligatoires et leurs utilisations
ES2732735T3 (es) Meganucleasas monocatenarias diseñadas racionalmente con secuencias de reconocimiento no palindrómicas
US20130061341A1 (en) Meganuclease variants cleaving a dna target sequence from a xp gene and uses thereof
WO2011141825A1 (fr) Variants de méganucléase clivant une séquence cible d'adn du gène de la rhodopsine et utilisations correspondantes
AU2007347328A1 (en) LAGLIDADG homing endonuclease variants having novel substrate specificity and use thereof
WO2011141820A1 (fr) Variants de méganucléase clivant une séquence cible d'adn du gène de dystrophine et leurs utilisations
CN103608027A (zh) 用于生成致密tale-核酸酶的方法及其用途
WO2009013559A1 (fr) Variants de méganucléase clivant une séquence cible d'adn à partir du gène bêta de l'hémoglobine humaine et ses utilisations
EP2171051A2 (fr) Procédé permettant d'améliorer l'activité de clivage de méganucléases issues de i-crei
WO2012010976A2 (fr) Variants de méganucléases clivant une séquence d'adn cible dans le gène tert et leurs utilisations
WO2012007848A2 (fr) Variants de méganucléase clivant une séquence d'adn cible dans le gène was et leurs utilisations
SG193850A1 (en) Meganuclease variants cleaving a dna target sequence from a glutamine synthetase gene and uses thereof

Legal Events

Date Code Title Description
AS Assignment

Owner name: CELLECTIS, FRANCE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ARNOULD, SYLVAIN;CHAMES, PATRICK;CHOULIKA, ANDRE';AND OTHERS;REEL/FRAME:017367/0415;SIGNING DATES FROM 20041209 TO 20041210

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION